CN1890213A - Process for preparing N-amino-substituted heterocyclic compounds - Google Patents
Process for preparing N-amino-substituted heterocyclic compounds Download PDFInfo
- Publication number
- CN1890213A CN1890213A CNA2004800357901A CN200480035790A CN1890213A CN 1890213 A CN1890213 A CN 1890213A CN A2004800357901 A CNA2004800357901 A CN A2004800357901A CN 200480035790 A CN200480035790 A CN 200480035790A CN 1890213 A CN1890213 A CN 1890213A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- integer
- solution
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Abstract
Description
发明背景Background of the Invention
发明领域field of invention
本发明涉及一种将含氮杂环化合物系列N-胺化的方法。更特别地,本发明涉及一种通过吲哚的N-胺化制备N-氨基吲哚的改进方法。本发明还涉及一种制备N-(正丙基)-N-(3-氟-4-吡啶基)-1H-3-甲基-吲哚-1-胺和由其衍生的产物的改进方法。The present invention relates to a method for N-amination of nitrogen-containing heterocyclic compound series. More particularly, the present invention relates to an improved process for the preparation of N-aminoindoles by N-amination of indoles. The present invention also relates to an improved process for the preparation of N-(n-propyl)-N-(3-fluoro-4-pyridyl)-1H-3-methyl-indol-1-amine and products derived therefrom .
现有技术的描述Description of prior art
多种N-氨基取代的氮杂环化合物已经被用作制备多种有机化合物的中间体,其尤其主要被用于药物应用。特别重要的一类氮杂环化合物是N-氨基吲哚类。在文献中已经报导了通常可以通过在溶剂例如二甲基甲酰胺(DMF)中于过量氢氧化钾的存在下将羟胺-O-磺酸(HOSA)逐份加入到吲哚中而进行吲哚类和其他氮杂环物质例如咔唑和吡咯的N-胺化,参见例如Somei,M.;Natsume,M.Tetrahedron Letters 1974,461。类似的例如吲哚类的N-胺化方法在美国专利No.5,459,274中作了描述,这些参考文献的全部内容在此引入作为参考。A variety of N-amino substituted nitrogen heterocyclic compounds have been used as intermediates in the preparation of various organic compounds, especially mainly for pharmaceutical applications. A particularly important class of nitrogen heterocycles are the N-aminoindoles. It has been reported in the literature that indole can generally be synthesized by adding hydroxylamine-O-sulfonic acid (HOSA) to indole in portions in the presence of excess potassium hydroxide in a solvent such as dimethylformamide (DMF). N-amination of carbazoles and other nitrogen heterocyclic substances such as carbazole and pyrrole, see for example Somei, M.; Natsume, M. Tetrahedron Letters 1974, 461. Similar methods for the N-amination of, for example, indoles are described in US Patent No. 5,459,274, the entire contents of which references are hereby incorporated by reference.
然而,上述方法存在一些限制,并且对于一些N-氢基吲哚的制备尤其相对于N-氨基吲哚的大规模和商业合成而言是不利的。例如,将吸湿的HOSA作为固体逐份加入会引起问题并且并不实用。另外,反应必须在多相条件下进行,从而导致不可接受的低产物产率。实际上,产物产率通常处于约40%的低水平下并且通常可根据所使用的氢氧化钾的表面积和质量以及反应介质的搅拌效率而变化。因此,该方法并不适用于规模扩大的操作。最重要的是通常会使用大量过量的碱,因此在产物的中和与加工之后必然存在过度的废物处理问题,由此使得该方法对于商业操作而言不经济。However, the above methods have some limitations and are disadvantageous for the preparation of some N-hydroindoles especially with respect to the large-scale and commercial synthesis of N-aminoindoles. For example, adding hygroscopic HOSA in portions as a solid is problematic and not practical. Additionally, the reaction must be performed under heterogeneous conditions, resulting in unacceptably low product yields. In practice, product yields are usually on the low level of about 40% and can generally vary depending on the surface area and mass of potassium hydroxide used and the stirring efficiency of the reaction medium. Therefore, this method is not suitable for scale-up operations. On top of that a large excess of base is usually used, so there is necessarily an excessive waste disposal problem after neutralization and processing of the product, thus making the process uneconomical for commercial operation.
在文献中还披露了可以在含水溶剂和无机碱的存在下使用HOSA而进行亚己基亚胺的N-胺化,参见例如EP专利申请No.0249452,该文献的全部内容在此引入作为参考。其中所披露的无机碱包括碱金属氢氧化物和碱土金属氢氧化物。特别地,在该方法中披露了可以通过将HOSA的水溶液和氢氧化钠的水溶液同时供入亚己基亚胺的水溶液中而进行N-胺化。然而,该方法类似地具有上文中所述的所有缺点,并且另外该方法特定地适用于亚己基亚胺-其是一种比许多其他氮杂环化合物例如吲哚类、咔唑类、吡咯类等更强的碱。尽管如此,所报导的产物产率也非常低。因此,需要一种用于含氮杂环化合物的N-胺化的改进方法。It is also disclosed in the literature that the N-amination of hexamethyleneimine can be carried out using HOSA in the presence of aqueous solvents and inorganic bases, see eg EP Patent Application No. 0249452, the entire content of which is hereby incorporated by reference. Inorganic bases disclosed therein include alkali metal hydroxides and alkaline earth metal hydroxides. In particular, it is disclosed in this method that N-amination can be carried out by simultaneously feeding an aqueous solution of HOSA and an aqueous solution of sodium hydroxide to an aqueous solution of hexamethyleneimine. However, this method similarly suffers from all the disadvantages described above, and in addition this method is specifically applicable to hexamethyleneimine - which is a more complex compound than many other nitrogen heterocycles such as indoles, carbazoles, pyrroles Wait for a stronger base. Nevertheless, the reported product yields are also very low. Therefore, there is a need for an improved method for the N-amination of nitrogen-containing heterocyclic compounds.
如上所述,如此形成的N-氨基氮杂环化合物可用作用于形成N-烷基氨基含氮化合物例如N-烷基氨基吲哚类的中间体。一般而言,可以在碱的存在下使用烷基化试剂例如卤代烷烃而进行氨基的N-烷基化。然而,这类烷基化反应通常会导致由杂环的竞争烷基化产生的显著量的副产物,因此是不希望的,参见例如美国专利No.5,459,274。另外,这类烷基化方法还会生成过度的副产物例如碱性卤化物,其必须进行处理,这使得它们不适用于工业上规模扩大的操作。As noted above, the N-aminonitrogen heterocyclic compounds so formed are useful as intermediates for the formation of N-alkylamino nitrogen-containing compounds such as N-alkylaminoindoles. In general, N-alkylation of amino groups can be carried out using an alkylating agent such as a haloalkane in the presence of a base. However, such alkylation reactions often result in significant amounts of by-products resulting from competing alkylation of heterocycles and are therefore undesirable, see eg US Patent No. 5,459,274. In addition, such alkylation processes also generate excessive by-products such as basic halides, which must be disposed of, making them unsuitable for industrial scale-up operations.
因此,本发明的一个目的是提供一种用于多种氮杂环化合物的N-胺化的新型均相方法。It was therefore an object of the present invention to provide a novel homogeneous process for the N-amination of a wide variety of nitrogen heterocycles.
本发明的另一目的是提供一种涉及有机碱的用于氮杂环化合物的N-胺化的方法,由此以高产率和以高纯度制备N-氨基杂环化合物。Another object of the present invention is to provide a process for the N-amination of nitrogen heterocyclic compounds involving organic bases, whereby N-aminoheterocyclic compounds are prepared in high yield and in high purity.
本发明的又一目的是提供一种新型N-烷基化方法,该方法不会导致任何副产物,由此提供高纯度的N-烷基氨基杂环化合物。Yet another object of the present invention is to provide a novel N-alkylation process which does not result in any by-products, thereby providing N-alkylaminoheterocyclic compounds of high purity.
本发明的其他目的和进一步的应用范围将从下面的详细描述中显见。Other objects and further scope of applicability of the present invention will be apparent from the following detailed description.
发明概述Summary of the invention
现已发现,可以在均相介质中使用有机碱和有机溶剂例如非质子溶剂而进行多种氮杂环化合物的N-胺化。因此,根据本发明的一个方面,提供了一种制备式II化合物的方法:It has now been found that the N-amination of a wide variety of nitrogen heterocycles can be carried out using organic bases and organic solvents, such as aprotic solvents, in a homogeneous medium. Therefore, according to one aspect of the present invention, a kind of method for preparing formula II compound is provided:
本发明的这方面的方法包括以下步骤:The method of this aspect of the invention comprises the steps of:
(a)在步骤(a)中,在合适的有机溶剂中制备羟胺-O-磺酸(HOSA)溶液;(a) in step (a), prepare a solution of hydroxylamine-O-sulfonic acid (HOSA) in a suitable organic solvent;
(b)在步骤(b)中,在合适的有机溶剂中制备合适碱的溶液;(b) in step (b), preparing a solution of a suitable base in a suitable organic solvent;
(c)在步骤(c)中,在合适的有机溶剂中制备式I化合物的溶液;(c) in step (c), a solution of the compound of formula I is prepared in a suitable organic solvent;
(d)最后在步骤(d)中,在合适的反应温度下将步骤(a)制备的溶液和步骤(b)制备的溶液同时以及成比例地加入到装在合适的反应容器中的步骤(c)制备的溶液中,从而以高纯度和高产率提供式(II)化合物,(d) finally in step (d), the solution prepared in step (a) and the solution prepared in step (b) are simultaneously and proportionally added to the step ( c) in the prepared solution, thereby providing the compound of formula (II) with high purity and high yield,
其中in
R是氢、C1-C4烷基、C1-C4烷氧基、苄氧基或者式CnHxFy或OCnHxFy的氟烷基或氟烷氧基,其中n为1~4的整数,x为0~8的整数,y为1~9的整数,并且x和y的总和为2n+1;R is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, benzyloxy or fluoroalkyl or fluoroalkoxy of the formula C n H x F y or OC n H x F y , wherein n is an integer from 1 to 4, x is an integer from 0 to 8, y is an integer from 1 to 9, and the sum of x and y is 2n+1;
R1和R2相同或不同并且彼此独立地选自氢、C1-C4烷基、C1-C4烷氧基、苄氧基或者式CnHxFy或OCnHxFy的氟烷基或氟烷氧基,其中n为1~4的整数,x为0~8的整数,y为1~9的整数,并且x和y的总和为2n+1;或者R 1 and R 2 are the same or different and are independently selected from hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, benzyloxy or the formula C n H x F y or OC n H x F fluoroalkyl or fluoroalkoxy of y , wherein n is an integer of 1 to 4, x is an integer of 0 to 8, y is an integer of 1 to 9, and the sum of x and y is 2n+1; or
R1和R2与它们连接的碳原子一起形成C5-C8环;和R 1 and R 2 together with the carbon atoms to which they are attached form a C 5 -C 8 ring; and
m为1或2。m is 1 or 2.
在本发明的另一方面中,还提供了另一种制备如本文中所述的式Ⅱ化合物的方法。本发明这一方面的方法包括以下步骤。在步骤(a)中,在合适的有机溶剂中制备羟胺-O-磺酸和如本文中所述的式I化合物的溶液。在步骤(b)中,在合适的有机溶剂中制备合适碱的溶液。在步骤(c)中,在合适的反应温度下将步骤(a)中制备的溶液与步骤(b)中制备的溶液同时以及成比例地接触,从而以高纯度和高产率提供式(II)化合物。其中R、R1、R2和m如上所定义。In another aspect of the present invention, there is also provided another process for preparing the compound of formula II as described herein. The method of this aspect of the invention comprises the following steps. In step (a), a solution of hydroxylamine-O-sulfonic acid and a compound of formula I as described herein is prepared in a suitable organic solvent. In step (b), a solution of a suitable base is prepared in a suitable organic solvent. In step (c), the solution prepared in step (a) is simultaneously and proportionally contacted with the solution prepared in step (b) at a suitable reaction temperature to provide formula (II) in high purity and high yield compound. wherein R, R 1 , R 2 and m are as defined above.
在本发明的另一方面中,还提供了一种制备式IV化合物的方法:In another aspect of the present invention, there is also provided a method for preparing the compound of formula IV:
在本发明的该方面中,该方法涉及以下这些。在合适的反应温度下将于合适有机溶剂中的羟胺-O-磺酸溶液和于合适有机溶剂中的合适碱溶液同时以及成比例地加入到于合适有机溶剂中的如本文中所述的式I化合物的溶液中,其中如本文中所述的式(I)化合物被装在合适的反应容器中。该反应可提供如本文中所述的式(II)化合物。In this aspect of the invention, the method involves the following. A solution of hydroxylamine-O-sulfonic acid in a suitable organic solvent and a solution of a suitable base in a suitable organic solvent are simultaneously and proportionally added to the formula as described herein in a suitable organic solvent at a suitable reaction temperature A solution of a compound of I, wherein a compound of formula (I) as described herein is packed in a suitable reaction vessel. This reaction can provide compounds of formula (II) as described herein.
然后在相同反应容器中将所得的N-氨基吲哚化合物(II)与式(III)化合物反应以提供式(IV)的化合物。The resulting N-aminoindole compound (II) is then reacted with a compound of formula (III) in the same reaction vessel to provide a compound of formula (IV).
其中R、R1、R2和m如上所定义,以及R3和R4相同或不同并且彼此独立地选自氢或C1-C4烷基。wherein R, R 1 , R 2 and m are as defined above, and R 3 and R 4 are the same or different and are independently selected from hydrogen or C 1 -C 4 alkyl.
最后,在本发明的另一方面中还提供了一种制备式VI化合物的方法:Finally, in another aspect of the present invention there is also provided a method for preparing the compound of formula VI:
在本发明的该方面中,该方法包括以下步骤:In this aspect of the invention, the method comprises the steps of:
在步骤(a)中,首先基本按照上述实施方案的步骤制备如本文中所述的式(IV)化合物。即,在合适的反应温度下将于合适有机溶剂中的羟胺-O-磺酸溶液和于合适有机溶剂中的合适碱溶液同时以及成比例地加入到于合适有机溶剂中的式I化合物的溶液中,其中如本文中所述的式(I)化合物被装在合适的反应容器中。该反应提供了如本文中所述的式(II)的化合物。然后在相同反应容器中将所得的N-氨基吲哚化合物(II)与式(III)化合物反应以提供式(IV)化合物。In step (a), the compound of formula (IV) as described herein is first prepared substantially according to the steps of the above embodiments. That is, at a suitable reaction temperature, a solution of hydroxylamine-O-sulfonic acid in a suitable organic solvent and a suitable base solution in a suitable organic solvent are simultaneously and proportionally added to a solution of the compound of formula I in a suitable organic solvent , wherein a compound of formula (I) as described herein is packed in a suitable reaction vessel. This reaction provides compounds of formula (II) as described herein. The resulting N-aminoindole compound (II) is then reacted with a compound of formula (III) in the same reaction vessel to provide a compound of formula (IV).
在本发明的该方法的步骤(b)中,将式(IV)化合物与合适的还原剂反应以提供式(V)化合物:In step (b) of the process of the invention, a compound of formula (IV) is reacted with a suitable reducing agent to provide a compound of formula (V):
最后,在本发明的该方法的步骤(c)中,然后在盐酸的存在下将式(V)化合物与式(VII)化合物Finally, in step (c) of the process of the invention, the compound of formula (V) is then combined with the compound of formula (VII) in the presence of hydrochloric acid
反应以提供作为其盐酸盐的式(VI)化合物。其中R、R1、R2、R3、R4和m如上所述。R5是氢、硝基、氨基、卤素、C1-4烷基、C1-4烷酰基氨基、苯基-C1-4烷酰基氨基、苯基羰基氨基、烷基氨基或苯基-C1-4烷基氨基;X是卤素;n为1或2,p为0或1。Reaction to provide the compound of formula (VI) as its hydrochloride salt. wherein R, R 1 , R 2 , R 3 , R 4 and m are as described above. R 5 is hydrogen, nitro, amino, halogen, C 1-4 alkyl, C 1-4 alkanoylamino, phenyl-C 1-4 alkanoylamino, phenylcarbonylamino, alkylamino or phenyl- C 1-4 alkylamino; X is halogen; n is 1 or 2, and p is 0 or 1.
在本发明的另一方面中,还提供了一种式(IV)化合物,其中所述取代基如本文中所述,条件是当R和R3是氢时,R4不是氢或甲基。In another aspect of the present invention there is also provided a compound of formula (IV), wherein said substituents are as described herein, with the proviso that when R and R3 are hydrogen, R4 is not hydrogen or methyl.
发明详述Detailed description of the invention
本文中所使用的术语具有如下含义:The terms used herein have the following meanings:
本文中所使用的措辞“C1-4烷基”包括甲基和乙基以及直链或支化的丙基和丁基。特定的烷基是甲基、乙基、正丙基、异丙基和叔丁基。可相应地理解所派生的措辞例如“C1-4烷氧基”、“苯基-C1-4烷基氨基”、“氨基-C1-4烷基”、“C1-4烷基氨基”、“单-或二-C1-4烷基氨基C1-4烷基”“二苯基-C1-4烷基”、“苯基-C1-4烷基”、“苯基羰基-C1-4烷基”和“苯氧基-C1-4烷基”。The expression "C 1-4 alkyl" as used herein includes methyl and ethyl as well as linear or branched propyl and butyl. Specific alkyl groups are methyl, ethyl, n-propyl, isopropyl and tert-butyl. Derived expressions such as "C 1-4 alkoxy", "phenyl-C 1-4 alkylamino", "amino-C 1-4 alkyl", "C 1-4 alkyl Amino", "mono- or di-C 1-4 alkylamino C 1-4 alkyl", "diphenyl-C 1-4 alkyl", "phenyl-C 1-4 alkyl", "benzene "Carbonyl-C 1-4 alkyl" and "phenoxy-C 1-4 alkyl".
本文中所使用的措辞“C1-6烷酰基”将具有与“C1-6酰基”相同的含义,其还可以从结构上表示为“R-CO-”,其中R如本文中所定义是C1-5烷基。另外,“C1-5烷基羰基”将与C1-6酰基的含义相同。特别地,“C1-6酰基”将是指甲酰基、乙酰基(acetyl)或乙酰基(ethanoyl)、丙酰基、正丁酰基等。可相应地理解所派生的措辞例如“C1-4酰氧基”、“C1-4酰氧基烷基”、“C1-6烷酰基氨基”、“苯基-C1-6烷酰基氨基”。The expression "C 1-6 alkanoyl" as used herein shall have the same meaning as "C 1-6 acyl", which may also be structurally represented as "R-CO-", wherein R is as defined herein is C 1-5 alkyl. In addition, "C 1-5 alkylcarbonyl" shall have the same meaning as C 1-6 acyl. In particular, "C 1-6 acyl" would be formyl, acetyl or ethanoyl, propionyl, n-butyryl and the like. Derived expressions such as "C 1-4 acyloxy", "C 1-4 acyloxyalkyl", "C 1-6 alkanoylamino", "phenyl-C 1-6 alkane" can be understood accordingly Acylamino".
本文中所使用的措辞“C1-6全氟烷基”是指所述烷基中的全部氢原子被氟原子代替。说明性实例包括三氟甲基和五氟乙基,以及直链或支化的七氟丙基、九氟丁基、十一氟戊基和十三氟己基。可相应地理解所派生的措辞“C1-6全氟烷氧基”。The expression "C 1-6 perfluoroalkyl" used herein means that all hydrogen atoms in the alkyl group are replaced by fluorine atoms. Illustrative examples include trifluoromethyl and pentafluoroethyl, and linear or branched heptafluoropropyl, nonafluorobutyl, undecafluoropentyl and tridecafluorohexyl. The derived expression "C 1-6 perfluoroalkoxy" is to be understood accordingly.
本文中所使用的措辞“杂芳基”包括所有公知的含杂原子的芳基。代表性的5元杂芳基包括呋喃基、噻吩基(thienyl)或噻吩基(thiophenyl)、吡咯基、异吡咯基、吡唑基、咪唑基、噁唑基、噻唑基等。代表性的6元杂芳基包括吡啶基、哒嗪基、嘧啶基、吡嗪基、三嗪基等基团。双环杂芳基的代表性实例包括苯并呋喃基、苯并噻吩基、吲哚基、喹啉基、异喹啉基等基团。The expression "heteroaryl" as used herein includes all known heteroatom-containing aryl groups. Representative 5-membered heteroaryl groups include furyl, thienyl or thiophenyl, pyrrolyl, isopyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, and the like. Representative 6-membered heteroaryl groups include pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like. Representative examples of bicyclic heteroaryl groups include benzofuryl, benzothienyl, indolyl, quinolinyl, isoquinolyl, and the like groups.
本文中所使用的措辞“杂环”包括所有公知的含杂原子的环状基团。代表性的5元杂环基团包括四氢呋喃基、四氢噻吩基、吡咯烷基、2-噻唑啉基、四氢噻唑基、四氢噁唑基等。代表性的6元杂环基团包括哌啶基、哌嗪基、吗啉基、硫代吗啉基等。许多其他的杂环基团包括但不限于吖丙啶基、氮杂环庚烷基、二氮杂环庚烷基、二氮杂双环[2.2.1]庚-2-基和三氮杂环庚烷基(triazocanyl)等。The expression "heterocycle" as used herein includes all known heteroatom-containing cyclic groups. Representative 5-membered heterocyclic groups include tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, 2-thiazolinyl, tetrahydrothiazolyl, tetrahydrooxazolyl, and the like. Representative 6-membered heterocyclic groups include piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and the like. Many other heterocyclic groups include, but are not limited to, aziridinyl, azepanyl, diazepanyl, diazabicyclo[2.2.1]hept-2-yl, and triazepanyl Heptyl (triazocanyl) and the like.
“卤素”或“卤代”是指氯、氟、溴和碘。"Halogen" or "halo" refers to chlorine, fluorine, bromine and iodine.
本文中所使用的“患者”是指温血动物,例如大鼠、小鼠、狗、猫、豚鼠和灵长类动物例如人类。"Patient" as used herein refers to warm-blooded animals such as rats, mice, dogs, cats, guinea pigs and primates such as humans.
本文中所使用的术语“药物可接受的盐”是指本发明的化合物的盐可用于医学应用。然而,其他盐也可以用在制备根据本发明的化合物或其药物可接受的盐中。合适的本发明化合物的药物可接受的盐包括酸加成盐,该盐可以例如通过将根据本发明的化合物的溶液与药物可接受的酸溶液混合而形成,这些药物可接受的酸例如为盐酸、氢溴酸、硫酸、甲烷磺酸、2-羟基乙烷磺酸、对-甲苯磺酸、富马酸、马来酸、羟基马来酸、苹果酸、抗坏血酸、琥珀酸、戊二酸、醋酸、水杨酸、肉桂酸、2-苯氧基苯甲酸、羟基苯甲酸、苯乙酸、苯甲酸、草酸、柠檬酸、酒石酸、乙醇酸、乳酸、丙酮酸、丙二酸、碳酸或磷酸。还可以形成酸金属盐例如正磷酸单氢钠(sodium monohydrogen orthophosphate)和硫酸氢钾。如此形成的盐还可以作为单-或二-酸盐存在,以及可以作为水合形式存在或者可以是基本无水的。此外,在本发明的化合物带有酸性部分的情况下,其合适的药物可接受的盐可以包括碱金属盐例如钠盐或钾盐;碱土金属盐例如钙盐或镁盐;以及与合适的有机配体形成的盐例如季铵盐。The term "pharmaceutically acceptable salt" as used herein means that the salts of the compounds of the present invention are useful in medical applications. However, other salts may also be used in the preparation of the compounds according to the invention or pharmaceutically acceptable salts thereof. Suitable pharmaceutically acceptable salts of compounds of the invention include acid addition salts which may be formed, for example, by mixing a solution of a compound according to the invention with a solution of a pharmaceutically acceptable acid, such as hydrochloric acid , hydrobromic acid, sulfuric acid, methanesulfonic acid, 2-hydroxyethanesulfonic acid, p-toluenesulfonic acid, fumaric acid, maleic acid, hydroxymaleic acid, malic acid, ascorbic acid, succinic acid, glutaric acid, Acetic acid, salicylic acid, cinnamic acid, 2-phenoxybenzoic acid, hydroxybenzoic acid, phenylacetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, carbonic acid, or phosphoric acid. Acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate may also be formed. The salts so formed may also exist as mono- or di-acid salts, and may exist in hydrated form or may be substantially anhydrous. In addition, where a compound of the present invention bears an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts such as sodium or potassium; alkaline earth metal salts such as calcium or magnesium; Ligand-formed salts such as quaternary ammonium salts.
措辞“立体异构体”是用于单个分子的所有异构体的通用术语,这些异构体的不同仅仅在于它们的原子在空间中的取向。一般而言,其包括通常由于至少一个不对称中心而形成的镜像异构体(对映体)。在根据本发明的化合物具有两个或更多个不对称中心的情况下,它们可以另外作为非对映异构体存在,某些单个分子也可以作为几何异构体(顺式/反式)存在。类似地,本发明的某些化合物可以以两种或更多种结构不同、迅速平衡的形式(通常称作互变异构体)的混合物存在。互变异构体的代表性实例包括酮-烯醇互变异构体、酚-酮互变异构体、亚硝基-肟互变异构体、亚胺-烯胺互变异构体等。应当理解的是所有这些异构体和其以任意比例的混合物被包含在本发明的范围内。The expression "stereoisomer" is a generic term for all isomers of individual molecules which differ only in the orientation of their atoms in space. In general, it includes mirror image isomers (enantiomers) which usually form as a result of at least one asymmetric center. In cases where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereomers, and certain individual molecules may also exist as geometric isomers (cis/trans) exist. Similarly, certain compounds of the present invention may exist as a mixture of two or more structurally distinct, rapidly equilibrating forms, commonly referred to as tautomers. Representative examples of tautomers include keto-enol tautomers, phenol-keto tautomers, nitroso-oxime tautomers, imine-enamine tautomers wait. It should be understood that all such isomers and mixtures thereof in any ratio are included within the scope of the present invention.
在广泛意义上,术语“取代”被认为包括了有机化合物的所有容许的取代基。在本文中所披露的若干特定实施方案中,术语“取代”是指被独立地选自以下基团的一种或多种取代基取代:C1-6烷基、C2-6链烯基、C1-6全氟烷基、苯基、羟基、-CO2H、酯、酰胺、C1-C6烷氧基、C1-C6硫代烷基、C1-C6全氟烷氧基、-NH2、Cl、Br、I、F、-NH-低级烷基和-N(低级烷基)2。然而,在这些实施方案中也可以使用本领域技术人员所公知的任何其他合适的取代基。In a broad sense, the term "substituted" is considered to include all permissible substituents of organic compounds. In several specific embodiments disclosed herein, the term "substituted" refers to being substituted by one or more substituents independently selected from the following groups: C 1-6 alkyl, C 2-6 alkenyl , C 1-6 perfluoroalkyl, phenyl, hydroxyl, -CO 2 H, ester, amide, C 1 -C 6 alkoxy, C 1 -C 6 thioalkyl, C 1 -C 6 perfluoro Alkoxy, -NH 2 , Cl, Br, I, F, -NH-lower alkyl and -N(lower alkyl) 2 . However, any other suitable substituents known to those skilled in the art may also be used in these embodiments.
因此,根据本发明的一个方面,提供了一种制备多种N-氨基取代杂环化合物的方法。从而在本发明的一个宽泛方面中,可以使用任何式(IA)的氮杂环化合物来制备相应的N-氨基-杂环化合物,如方案1中所示。Therefore, according to one aspect of the present invention, there is provided a method for preparing various N-amino substituted heterocyclic compounds. Thus in one broad aspect of the invention, any nitrogen heterocyclic compound of formula (IA) can be used to prepare the corresponding N-amino-heterocyclic compound, as shown in Scheme 1 .
方案1 plan 1
可用于本发明方法的式(IA)的单环氮杂环化合物的代表性实例包括但不限于取代或未取代的吡咯、吡唑、咪唑、1,2,3-三唑、1,2,4-三唑等。可用于本发明方法的式(IA)的双环氮杂环化合物的代表性实例包括但不限于取代或未取代的吲哚、4、5、6或7-氮杂-吲哚、嘌呤、吲唑、4、5、6或7-氮杂-吲唑、苯并咪唑、4,7-二氮杂吲哚和多种其他异构的二氮杂吲哚等。可用于本发明方法的式(IA)的三环氮杂环化合物的代表性实例包括但不限于取代或未取代的咔唑或者多种公知的杂原子取代的咔唑。如上文中所定义,在上述取代的杂环化合物的情形中可以使用任何可能的取代基,条件是这些取代基不会干扰本发明的方法。Representative examples of monocyclic nitrogen heterocyclic compounds of formula (IA) useful in the methods of the invention include, but are not limited to, substituted or unsubstituted pyrroles, pyrazoles, imidazoles, 1,2,3-triazoles, 1,2, 4-triazole etc. Representative examples of bicyclic nitrogen heterocyclic compounds of formula (IA) useful in the methods of the invention include, but are not limited to, substituted or unsubstituted indole, 4, 5, 6 or 7-aza-indole, purine, indazole , 4, 5, 6 or 7-aza-indazole, benzimidazole, 4,7-diazaindole and various other isomeric diazaindole, etc. Representative examples of tricyclic nitrogen heterocyclic compounds of formula (IA) that may be used in the methods of the present invention include, but are not limited to, substituted or unsubstituted carbazoles or a variety of well-known heteroatom-substituted carbazoles. As defined above, any possible substituents may be used in the case of the above substituted heterocyclic compounds, provided that these substituents do not interfere with the process of the invention.
因此,在本发明的一个特定实施方案中提供了一种制备式Ⅱ的化合物的方法:Therefore, in a particular embodiment of the present invention there is provided a process for the preparation of compounds of formula II:
本发明该方面的方法包括以下步骤:The method of this aspect of the invention comprises the steps of:
(a)在步骤(a)中,在合适的有机溶剂中制备羟胺-O-磺酸(HOSA)溶液;(a) in step (a), prepare a solution of hydroxylamine-O-sulfonic acid (HOSA) in a suitable organic solvent;
(b)在步骤(b)中,在合适的有机溶剂中制备合适碱的溶液;(b) in step (b), preparing a solution of a suitable base in a suitable organic solvent;
(c)在步骤(c)中,在合适的有机溶剂中制备式I化合物的溶液;(c) in step (c), a solution of the compound of formula I is prepared in a suitable organic solvent;
(d)最后在步骤(d)中,在合适的反应温度下将步骤(a)制备的溶液和步骤(b)制备的溶液同时以及成比例地加入到装在合适的反应容器中的步骤(c)制备的溶液中,从而以高纯度和高产率提供式(II)化合物,(d) finally in step (d), the solution prepared in step (a) and the solution prepared in step (b) are simultaneously and proportionally added to the step ( c) in the prepared solution, thereby providing the compound of formula (II) with high purity and high yield,
其中in
R是氢、C1-C4烷基、C1-C4烷氧基、苄氧基或者式CnHxFy或OCnHxFy的氟烷基或氟烷氧基,其中n为1~4的整数,x为0~8的整数,y为1~9的整数,并且x和y的总和为2n+1;R is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, benzyloxy or fluoroalkyl or fluoroalkoxy of the formula C n H x F y or OC n H x F y , wherein n is an integer from 1 to 4, x is an integer from 0 to 8, y is an integer from 1 to 9, and the sum of x and y is 2n+1;
R1和R2相同或不同并且彼此独立地选自氢、C1-C4烷基、C1-C4烷氧基、苄氧基或者式CnHxFy或OCnHxFy的氟烷基或氟烷氧基,其中n为1~4的整数,x为0~8的整数,y为1~9的整数,并且x和y的总和为2n+1;或者R 1 and R 2 are the same or different and are independently selected from hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, benzyloxy or the formula C n H x F y or OC n H x F fluoroalkyl or fluoroalkoxy of y , wherein n is an integer of 1 to 4, x is an integer of 0 to 8, y is an integer of 1 to 9, and the sum of x and y is 2n+1; or
R1和R2与它们连接的碳原子一起形成C5-C8环;和R 1 and R 2 together with the carbon atoms to which they are attached form a C 5 -C 8 ring; and
m为1或2。m is 1 or 2.
应当注意的是可以使用如上文中所述的步骤来制备式(II)化合物,不一定在不同的反应容器中但是可以在相同的反应容器中基本使用这些步骤进行。同样,如果必要,可以通过改变这些步骤的顺序来改变反应物加入的顺序。It should be noted that the compounds of formula (II) may be prepared using the procedures as described hereinabove, not necessarily in different reaction vessels but essentially using these steps in the same reaction vessel. Also, the order of addition of reactants can be altered, if necessary, by altering the order of these steps.
在本发明方法的一个方面中,可以将本领域技术人员所公知的任何合适的有机溶剂用于本发明方法的步骤(a)和(b)。可以使用的具体类型的有机溶剂广泛地包括极性非质子溶剂以及多种非极性非质子溶剂或其混合物。本文中所使用的非质子有机溶剂是指该溶剂既不是质子给体也不是质子受体。一般而言,非质子溶剂更适合于本发明方法的步骤(a)和(b)。In one aspect of the method of the invention, any suitable organic solvent known to those skilled in the art may be used in steps (a) and (b) of the method of the invention. Specific types of organic solvents that can be used broadly include polar aprotic solvents as well as various nonpolar aprotic solvents or mixtures thereof. As used herein, an aprotic organic solvent means that the solvent is neither a proton donor nor a proton acceptor. In general, aprotic solvents are more suitable for steps (a) and (b) of the process of the invention.
适合于本发明方法的非质子溶剂的代表性实例包括但不限于N-甲基吡咯烷酮(NMP)、N,N-二甲基甲酰胺(DMF)、二甲基乙酰胺(DMAc)、二甲基亚砜(DMSO)、六甲基磷酰胺(HMPA)等。也可以使用这些溶剂以任意比例的混合物。非极性有机溶剂的实例包括但不限于四氢呋喃(THF)、正己烷、正庚烷、石油醚等。也可以使用多种卤化溶剂例如二氯甲烷、氯仿、四氯化碳、1,2-二氯乙烷等。另外还可以使用任何极性和非极性溶剂的其它组合,例如NMP/己烷、NMP/庚烷等。Representative examples of aprotic solvents suitable for the process of the invention include, but are not limited to, N-methylpyrrolidone (NMP), N,N-dimethylformamide (DMF), dimethylacetamide (DMAc), dimethyl sulfoxide (DMSO), hexamethylphosphoramide (HMPA), etc. Mixtures of these solvents in arbitrary proportions can also be used. Examples of non-polar organic solvents include, but are not limited to, tetrahydrofuran (THF), n-hexane, n-heptane, petroleum ether, and the like. A variety of halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, and the like can also be used. Also other combinations of any polar and non-polar solvents can be used, such as NMP/hexane, NMP/heptane, etc.
如所述的那样,本发明方法在本发明方法的步骤(b)中使用了碱。一般而言,可以产生所需作用的任何碱可用于本发明方法的该步骤。在该步骤中通常有利的是使用有机碱,尤其是可溶于所使用的溶剂的有机碱。因此,该反应可以均相方式进行。另外,pKa值至少大约与吲哚的pKa值相同的碱更适合于本发明方法的该步骤。As stated, the process of the invention uses a base in step (b) of the process of the invention. In general, any base that produces the desired effect can be used in this step of the process of the invention. It is generally advantageous in this step to use organic bases, especially organic bases which are soluble in the solvent used. Therefore, the reaction can proceed in a homogeneous manner. Additionally, bases having a pKa value at least about the same as that of indole are more suitable for this step of the method of the invention.
用于该步骤的合适的有机碱包括碱金属醇盐。合适的碱金属醇盐的实例包括但不限于甲醇锂、乙醇锂、异丙醇锂、叔丁醇锂、甲醇钠、乙醇钠、异丙醇钠、叔丁醇钠、甲醇钾、乙醇钾、异丙醇钾、叔丁醇钾、甲醇铯、乙醇铯、异丙醇铯和叔丁醇铯等。也可以使用这些有机碱的混合物。已经发现在本发明方法的实践中,叔丁醇钾是特别合适的碱金属醇盐。Suitable organic bases for this step include alkali metal alkoxides. Examples of suitable alkali metal alkoxides include, but are not limited to, lithium methoxide, lithium ethoxide, lithium isopropoxide, lithium t-butoxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, sodium t-butoxide, potassium methoxide, potassium ethoxide, Potassium isopropoxide, potassium tert-butoxide, cesium methoxide, cesium ethoxide, cesium isopropoxide and cesium tert-butoxide, etc. Mixtures of these organic bases can also be used. Potassium tert-butoxide has been found to be a particularly suitable alkali metal alkoxide in the practice of the process of the invention.
在本发明方法的步骤(c)中,所使用的溶剂也是非质子溶剂。上面列出的任何非质子溶剂可用于本发明方法的该步骤。与步骤(a)和(b)中所使用的相同溶剂也可用于该步骤。例如,这些非质子溶剂包括但不限于NMP、DMF、DMAc等和/或其混合物。In step (c) of the process according to the invention, the solvent used is also an aprotic solvent. Any of the aprotic solvents listed above may be used in this step of the process of the invention. The same solvents as used in steps (a) and (b) can also be used in this step. For example, such aprotic solvents include, but are not limited to, NMP, DMF, DMAc, etc. and/or mixtures thereof.
在本发明的方法中可以采用产生预期结果的任何反应温度。一般而言,合适的反应温度可以处于亚环境温度(subambient temperature)至环境温度的范围内。例如,约为-5℃至约40℃的反应温度适合于实施本发明的方法。甚至更合适的是,约为0℃至约25℃的反应温度可以用于本发明的方法中。本领域技术人员通常会理解和认识到更高的温度通常可提高反应速率。因此在某些情况下可以采用超环境温度(superambient temperature,即高于室温)直至所述溶剂的回流温度。Any reaction temperature that produces the desired result can be employed in the process of the invention. In general, suitable reaction temperatures may be in the range of subambient temperature to ambient temperature. For example, reaction temperatures of from about -5°C to about 40°C are suitable for carrying out the methods of the present invention. Even more suitably, reaction temperatures from about 0°C to about 25°C can be used in the process of the invention. Those skilled in the art generally understand and appreciate that higher temperatures generally increase the reaction rate. Thus in some cases superambient temperatures (ie above room temperature) up to the reflux temperature of the solvent can be used.
一般而言,采用过量的碱来进行本发明的方法。例如,所述碱可以以相对于式I化合物为约1mol~约10mol的量存在。然而,为了实施本发明的方法,所述碱可以以相对于式I化合物为约3mol~约6mol的量存在。In general, the process of the invention is carried out with an excess of base. For example, the base may be present in an amount of about 1 mol to about 10 mol relative to the compound of formula I. However, for carrying out the method of the present invention, the base may be present in an amount of about 3 mol to about 6 mol relative to the compound of formula I.
类似地,当与式(I)化合物相比时,HOSA过量存在。在本发明的方法中通常有利的是使用多于一摩尔过量的HOSA。更有利地,现已发现,仅仅约2摩尔过量的HOSA足以产生通过实践本发明的最佳结果。Similarly, HOSA is present in excess when compared to the compound of formula (I). It is generally advantageous to use more than a molar excess of HOSA in the process of the invention. More advantageously, it has now been found that only about a 2 molar excess of HOSA is sufficient to produce the best results by practicing the invention.
可以通过本领域中任何公知的方法来进行步骤(a)和(b)中制备的反应溶液与得自于步骤(c)的反应物溶液的接触。例如,但不限于此,步骤(d)中的所述接触可以在其中连续供入反应物的连续式反应器中、或者通过静态混合例如具有有限停留时间的静态混合或与回路系统组合的静态混合、或者通过微反应器而进行。为此,可以使用多种公知的静态混合器、连续式反应器和微反应器。连续的反应可以通过本领域公知的方法以连续的方式或者分批地进行。The contacting of the reaction solution prepared in steps (a) and (b) with the reactant solution obtained from step (c) can be carried out by any method known in the art. For example, but not limited thereto, said contacting in step (d) may be in a continuous reactor in which the reactants are continuously fed, or by static mixing such as static mixing with limited residence time or static mixing in combination with a loop system. Mixing, or through a microreactor. For this purpose, various known static mixers, continuous reactors and microreactors can be used. Continuous reactions can be carried out in a continuous manner or batchwise by methods well known in the art.
也可以在间歇式反应器中进行步骤(d)中的接触。可以采用产生所希望结果的任何公知的反应器。例如,在间歇式操作中将得自于步骤(a)和(b)的反应溶液供入含有得自于步骤(c)的反应溶液的反应器例如搅拌釜反应器。本领域技术人员所公知的多种变换方式可以用于以这种操作模式影响这些反应溶液的加入。It is also possible to carry out the contacting in step (d) in a batch reactor. Any known reactor that produces the desired result can be used. For example, in a batch operation the reaction solutions from steps (a) and (b) are fed to a reactor containing the reaction solution from step (c), such as a stirred tank reactor. Various permutations known to those skilled in the art can be used to effect the addition of the reaction solutions in this mode of operation.
如上文中所述,在本发明的方法中可以使用多种氮杂环化合物。例如,在无任何限制的情况下,可以在本发明的方法中使用其中R和R1是氢以及R2是甲基的式(I)化合物。其中R1和R2与它们连接的碳原子一起形成苯环的式(I)化合物也是优选的。这些化合物的具体实例如上文中所述。例如,可以使用取代或未取代的咔唑。As noted above, a wide variety of nitrogen heterocyclic compounds can be used in the methods of the present invention. For example, without any limitation, compounds of formula (I) wherein R and R 1 are hydrogen and R 2 is methyl may be used in the methods of the invention. Compounds of formula (I) wherein R 1 and R 2 together with the carbon atoms to which they are attached form a benzene ring are also preferred. Specific examples of these compounds are described above. For example, substituted or unsubstituted carbazoles can be used.
在本发明的另一方面中,还提供了另一种制备如本文中所述的式Ⅱ化合物的方法。本发明该方面的方法包括以下步骤。在步骤(a)中,在合适的有机溶剂中制备羟胺-O-磺酸和如本文中所述的式I化合物的溶液。在步骤(b)中,在合适的有机溶剂中制备合适碱的溶液。在步骤(c)中,在合适的反应温度下将步骤(a)中制备的溶液与步骤(b)中制备的溶液同时以及成比例地接触,从而以高纯度和高产率提供式(II)化合物。其中R、R1、R2和m如上所定义。In another aspect of the present invention, there is also provided another process for preparing the compound of formula II as described herein. The method of this aspect of the invention comprises the following steps. In step (a), a solution of hydroxylamine-O-sulfonic acid and a compound of formula I as described herein is prepared in a suitable organic solvent. In step (b), a solution of a suitable base is prepared in a suitable organic solvent. In step (c), the solution prepared in step (a) is simultaneously and proportionally contacted with the solution prepared in step (b) at a suitable reaction temperature to provide formula (II) in high purity and high yield compound. wherein R, R 1 , R 2 and m are as defined above.
此外,可以使用本领域公知的任何反应器来进行上述的本发明方法。例如,但不限于此,可以使用搅拌釜反应器、连续式反应器、微反应器或静态混合器。上述本发明方法特别适合于在连续式搅拌釜反应器中进行所述胺化反应。Furthermore, any reactor known in the art may be used to carry out the process of the invention described above. For example, without limitation, stirred tank reactors, continuous reactors, microreactors, or static mixers may be used. The process of the invention described above is particularly suitable for carrying out the amination reaction in a continuous stirred tank reactor.
在本发明的该实施方案中,可以使用适合于进行该反应的任何溶剂。更合适地,在该实施方案中还可以使用如上文中所述的所有溶剂。一般而言,如本文中所述的非质子溶剂例如NMP、DMF或DMAc是更合适的溶剂。In this embodiment of the invention, any solvent suitable for carrying out the reaction may be used. More suitably, all solvents as described above can also be used in this embodiment. In general, aprotic solvents such as NMP, DMF or DMAc as described herein are more suitable solvents.
在该实施方案中,所用的碱是产生预期结果的那些。可以使用任何公知的碱。然而更合适的是,在本发明的该实施方案中可以使用例如上述有机碱的碱。一般而言,更合适的是使用可溶于如上文中所述用作反应溶剂的有机碱。适合于该实施方案的有机碱的具体实例包括碱金属醇盐例如叔丁醇钾。In this embodiment, the bases used are those that produce the desired results. Any known base can be used. More suitably, however, bases such as the above-mentioned organic bases may be used in this embodiment of the invention. In general, it is more suitable to use an organic base which is soluble in the reaction solvent as described above. Specific examples of organic bases suitable for this embodiment include alkali metal alkoxides such as potassium t-butoxide.
本领域技术人员同样理解的是,在本发明的该实施方案中可以使用产生预期结果的任何反应温度。为了重申,如上文中所述,亚环境温度至环境温度通常适合于进行本发明的该方法。然而,在某些情况下也可以使用超环境温度。It will also be appreciated by those skilled in the art that any reaction temperature that produces the desired results may be used in this embodiment of the invention. To reiterate, as noted above, sub-ambient to ambient temperatures are generally suitable for carrying out the method of the invention. However, super-ambient temperatures may also be used in some cases.
此外,通常有利的是使用当与式(I)化合物相比过量的碱以及HOSA来进行本发明的该方法。更有利的是,如上所述,甚至在该实施方案中,仅仅约2摩尔过量的HOSA足以产生最佳结果。类似地,如上文中所述,可以使用约1mol~约10mol过量的碱,但是碱可以以相对于式I化合物为约3mol~约6mol的量存在。Furthermore, it is often advantageous to carry out the process of the invention using an excess of base and HOSA when compared to the compound of formula (I). Even more advantageously, as noted above, even in this embodiment, only about a 2 molar excess of HOSA is sufficient to produce optimal results. Similarly, as described above, the base may be used in an excess of from about 1 molar to about 10 molar, but the base may be present in an amount of from about 3 molar to about 6 molar relative to the compound of formula I.
在本发明的另一方面中,还提供了一种制备式IV化合物的方法:In another aspect of the present invention, there is also provided a method for preparing the compound of formula IV:
在本发明的该方面中,该方法包括以下这些。在合适的反应温度下将于合适有机溶剂中的羟胺-O-磺酸溶液和于合适有机溶剂中的合适的碱溶液同时以及成比例地加入到于合适有机溶剂中的如本文中所述的式I化合物的溶液中,其中如本文中所述的式(I)化合物被装在如上所述的合适反应容器中。该反应提供了如本文中所述的式(II)化合物。In this aspect of the invention, the method includes the following. A solution of hydroxylamine-O-sulfonic acid in a suitable organic solvent and a suitable base solution in a suitable organic solvent are simultaneously and proportionally added to the compound as described herein in a suitable organic solvent at a suitable reaction temperature. A solution of a compound of formula I wherein a compound of formula (I) as described herein is packed in a suitable reaction vessel as described above. This reaction provides compounds of formula (II) as described herein.
然后在相同反应容器中将所得的N-氨基-吲哚化合物(II)与式(III)化合物反应以提供式(IV)化合物。The resulting N-amino-indole compound (II) is then reacted with a compound of formula (III) in the same reaction vessel to provide a compound of formula (IV).
其中R、R1、R2和m如上所定义,以及R3和R4相同或不同并且彼此独立地选自氢或C1-C4烷基。wherein R, R 1 , R 2 and m are as defined above, and R 3 and R 4 are the same or different and are independently selected from hydrogen or C 1 -C 4 alkyl.
在本发明的该实施方案中,采用基本类似于如上所述的本发明的其他两个实施方案中的步骤来进行式(I)化合物到式(II)化合物的胺化。因此,在该实施方案中可以使用上述所有的溶剂、碱和反应容器。类似地,可以使用与上述相同的反应条件。一般而言,可以采用在约-5℃至约40℃的温度范围内的非质子溶剂例如NMP、DMF或DMAc和有机碱例如叔丁醇钾以及HOSA。特别优选约0℃至约25℃的温度。In this embodiment of the invention, the amination of the compound of formula (I) to the compound of formula (II) is carried out using substantially similar procedures as described above in the other two embodiments of the invention. Thus, all of the solvents, bases and reaction vessels described above can be used in this embodiment. Similarly, the same reaction conditions as above can be used. In general, aprotic solvents such as NMP, DMF or DMAc and organic bases such as potassium tert-butoxide and HOSA in the temperature range of about -5°C to about 40°C can be employed. Temperatures from about 0°C to about 25°C are particularly preferred.
此外,如上所述,通常有利的是使用当与式(I)化合物相比过量的碱以及HOSA来进行本发明的该方法。更有利的是,如上所述,甚至在该实施方案中,仅仅约2摩尔过量的HOSA足以产生最佳的结果。类似地,如上文中所述,可以使用约1mol~约10mol过量的碱,但是碱可以以相对于式I化合物为约3mol~约6mol的量存在。Furthermore, as mentioned above, it is often advantageous to carry out the process of the invention using an excess of base and HOSA when compared to the compound of formula (I). Even more advantageously, as noted above, even in this embodiment, only about a 2 molar excess of HOSA is sufficient to produce optimal results. Similarly, as described above, the base may be used in an excess of from about 1 molar to about 10 molar, but the base may be present in an amount of from about 3 molar to about 6 molar relative to the compound of formula I.
有利的是,现已发现可以在相同的反应容器中通过加入式(III)化合物来进行式(II)化合物与式(III)化合物的反应。一般而言,可以在式(II)化合物形成之后单独加入式(III)化合物。然而,可以有利地加入一些有机酸或无机酸。合适的有机酸包括醋酸、丙酸、正丁酸等。还发现使用水与有机酸是有利的。合适的无机酸包括盐酸、硝酸、硫酸等。通常将酸加到一定量以使得反应介质保持在约为4的pH。Advantageously, it has now been found that the reaction of a compound of formula (II) with a compound of formula (III) can be carried out by adding a compound of formula (III) in the same reaction vessel. In general, the compound of formula (III) can be added separately after the compound of formula (II) is formed. However, some organic or inorganic acid may advantageously be added. Suitable organic acids include acetic acid, propionic acid, n-butyric acid, and the like. It has also been found advantageous to use water with an organic acid. Suitable inorganic acids include hydrochloric acid, nitric acid, sulfuric acid, and the like. The acid is usually added in such an amount that the reaction medium is maintained at a pH of about 4.
该加成反应通常可以在环境温度下进行,但是也可以根据所使用的式(II)和(III)化合物的种类采用亚环境温度至超环境温度。一般而言,可以采用约0℃~约100℃的温度。约5℃~约30℃的温度是优选的。更特别地优选约20℃的环境温度。The addition reaction can generally be carried out at ambient temperature, but sub-ambient to super-ambient temperatures can also be employed depending on the type of compound of formula (II) and (III) used. Generally, temperatures from about 0°C to about 100°C can be employed. A temperature of about 5°C to about 30°C is preferred. Ambient temperatures of about 20° C. are more particularly preferred.
在本发明的该方法中可以使用多种式(III)化合物。这些化合物的实例包括但不限于多种公知的醛和酮。醛的具体实例包括但不限于甲醛、乙醛、丙醛、正丁醛、异丁醛、苯甲醛、苯乙醛等。用于该方法的合适的酮包括但不限于丙酮、甲基乙基酮、二乙基酮、苯乙酮、二苯甲酮等。一般而言,在本发明的该方法中醛是更合适的反应物,丙醛是最合适的式(Ⅲ)化合物。A variety of compounds of formula (III) can be used in the method of the invention. Examples of these compounds include, but are not limited to, various well-known aldehydes and ketones. Specific examples of aldehydes include, but are not limited to, formaldehyde, acetaldehyde, propionaldehyde, n-butyraldehyde, isobutyraldehyde, benzaldehyde, phenylacetaldehyde, and the like. Suitable ketones for this method include, but are not limited to, acetone, methyl ethyl ketone, diethyl ketone, acetophenone, benzophenone, and the like. In general, aldehydes are more suitable reactants in the process of the invention, with propionaldehyde being the most suitable compound of formula (III).
在本发明的另一方面中,本发明的一个实施方案包括根据本发明的该方法制备的产物。特别地,根据本发明所述方法制备的产物的R、R1和R4是氢,R2是甲基,和R3是乙基。更特别地,根据本发明所述方法制备的产物是3-甲基-N-(丙叉基)-1H-吲哚-1-胺。In another aspect of the invention, an embodiment of the invention includes the product prepared according to the method of the invention. In particular, R, R1 and R4 of the product prepared according to the process of the present invention are hydrogen, R2 is methyl, and R3 is ethyl. More particularly, the product prepared according to the process of the present invention is 3-methyl-N-(propylidene)-1H-indol-1-amine.
最后,在本发明的另一方面中还提供了一种制备式Ⅵ化合物的方法:Finally, in another aspect of the present invention, a method for preparing the compound of formula VI is also provided:
在本发明的该方面中,该方法包括以下步骤:In this aspect of the invention, the method comprises the steps of:
在本发明的该方法实施方案的步骤(a)中,首先基本按照上述实施方案的步骤制备如本文中所述的式(IV)化合物。即,在合适的反应温度下将于合适有机溶剂中的羟胺-O-磺酸溶液和于合适有机溶剂中的合适的碱溶液同时以及成比例地加入到于合适有机溶剂中的式I化合物的溶液中,其中如本文中所述的式(I)化合物被装在合适的反应容器中。该反应提供了如本文中所述的式(II)化合物。In step (a) of this method embodiment of the invention, the compound of formula (IV) as described herein is first prepared substantially according to the steps of the above embodiments. That is, at a suitable reaction temperature, the hydroxylamine-O-sulfonic acid solution in a suitable organic solvent and the suitable alkali solution in a suitable organic solvent are simultaneously and proportionally added to the compound of formula I in a suitable organic solvent In solution, wherein a compound of formula (I) as described herein is packed in a suitable reaction vessel. This reaction provides compounds of formula (II) as described herein.
然后在相同的反应容器中将所得的N-氨基-吲哚化合物(II)与式(III)化合物反应以提供式(IV)化合物。The resulting N-amino-indole compound (II) is then reacted with a compound of formula (III) in the same reaction vessel to provide a compound of formula (IV).
在本发明的该方法的步骤(b)中,将式(IV)化合物与合适的还原剂反应以提供式(V)化合物:In step (b) of the process of the invention, a compound of formula (IV) is reacted with a suitable reducing agent to provide a compound of formula (V):
最后,在本发明的该方法的步骤(c)中,然后在合适的有机溶剂中在合适的碱存在下将式(V)化合物与式(VII)化合物反应,Finally, in step (c) of the process of the invention, a compound of formula (V) is then reacted with a compound of formula (VII) in a suitable organic solvent in the presence of a suitable base,
以提供式(VI)化合物。任选地使用无机酸例如盐酸处理式(VI)化合物以提供式(VI)化合物的盐(例如盐酸盐)。其中R、R1、R2、R3、R4和m如上所述。R5是氢、硝基、氨基、卤素、C1-4烷基、C1-4烷酰基氨基、苯基-C1-4烷酰基氨基、苯基羰基氨基、烷基氨基或苯基-C1-4烷基氨基;X是卤素;n为1或2和p为0或1。to provide a compound of formula (VI). Compounds of formula (VI) are optionally treated with a mineral acid such as hydrochloric acid to provide salts (eg hydrochloride salts) of compounds of formula (VI). wherein R, R 1 , R 2 , R 3 , R 4 and m are as described above. R 5 is hydrogen, nitro, amino, halogen, C 1-4 alkyl, C 1-4 alkanoylamino, phenyl-C 1-4 alkanoylamino, phenylcarbonylamino, alkylamino or phenyl- C 1-4 alkylamino; X is halogen; n is 1 or 2 and p is 0 or 1.
还将理解的是上文中所述的步骤仅仅是出于说明的目的。实施这些步骤的顺序可以改变和/或可以同时和/或并发地进行这些步骤中的一个或多个。因此,这些步骤的多种变换方案同样构成本发明的一部分。更有利地,所有这些步骤可以在相同的反应容器中以单个间歇式操作或者在连续式反应器中进行。It will also be understood that the steps described above are for illustration purposes only. The order in which these steps are performed may be changed and/or one or more of these steps may be performed simultaneously and/or concurrently. Accordingly, various variations of these steps also form part of the invention. More advantageously, all these steps can be carried out in the same reaction vessel as a single batch operation or in a continuous reactor.
因此根据本发明的该方面,在该实施方案的步骤(a)中,基本以与上述相同的方式通过在大约亚环境反应温度至环境反应温度下使用溶剂(优选非质子溶剂)、碱(优选有机碱)和HOSA而进行式(I)化合物的胺化以形成式(II)化合物。Thus according to this aspect of the invention, in step (a) of this embodiment, in substantially the same manner as described above, by using a solvent (preferably an aprotic solvent), a base (preferably organic base) and HOSA to carry out the amination of the compound of formula (I) to form the compound of formula (II).
然后将如此形成的式(II)化合物转化成式(IV)化合物,通常在相同的反应容器中,如上所述通过使式(II)化合物与式(III)化合物反应。反应条件和合适的式(III)化合物与上述的那些相同。The compound of formula (II) thus formed is then converted to a compound of formula (IV), usually in the same reaction vessel, by reacting a compound of formula (II) with a compound of formula (III) as described above. The reaction conditions and suitable compounds of formula (III) are the same as those described above.
如所述的那样,然后将式(IV)化合物还原成式(V)化合物。可以使用本领域的任何公知方法进行该还原反应。一般而言,可以使用任何公知的C=N还原剂(例如通常用于还原席夫碱、腙或亚胺的那些)进行该还原。合适的还原剂的实例包括但不限于氢化铝锂、硼氢化钠、硼氢化钠和冰醋酸、乙酰氧基硼氢化钠、二乙酰氧基硼氢化钠、三乙酰氧基硼氢化钠、氰基硼氢化钠、乙醇钠、氢气和催化剂等。Compounds of formula (IV) are then reduced to compounds of formula (V), as described. This reduction can be carried out using any method known in the art. In general, this reduction can be carried out using any known C=N reducing agent such as those commonly used to reduce Schiff bases, hydrazones or imines. Examples of suitable reducing agents include, but are not limited to, lithium aluminum hydride, sodium borohydride, sodium borohydride and glacial acetic acid, sodium acetoxyborohydride, sodium diacetoxyborohydride, sodium triacetoxyborohydride, cyano Sodium borohydride, sodium ethoxide, hydrogen and catalysts, etc.
也可以使用其他还原剂例如于HMPA中的二丁基锡氯化氢(Bu2SnClH)。还可以使用多种硼试剂。具体实例包括:乙硼烷、硼-硫化物络合物例如硼-二甲基硫化物或者硼-1,4-噻噁烷络合物;硼醚合物例如硼-THF络合物;硼-胺络合物例如硼-氨、硼-叔丁胺、硼-N-乙基-二异丙胺、硼-N-乙基吗啉、硼-N-甲基吗啉、硼-吗啉、硼-哌啶、硼-吡啶、硼-三乙胺和硼-三甲基胺;硼-膦络合物例如硼-三丁基膦或硼-三苯基膦;硼氢化物的混合物例如硼氢化钠和硼氢化四烷基铵;原位生成硼烷的试剂,例如硼氢化钠和碘、硼氢化钠和BF3-二乙醚合物、硼氢化钠和氯三甲基硅烷、硼氢化四烷基铵和烷基溴化物例如正丁基溴的组合;等等。现已发现在本发明方法的该步骤中,在冰醋酸存在下的硼氢化钠通常是一种更合适的还原剂。Other reducing agents such as dibutyltin hydrochloride ( Bu2SnClH ) in HMPA can also be used. A variety of boron reagents can also be used. Specific examples include: diborane, boron-sulfide complexes such as boron-dimethylsulfide or boron-1,4-thioxane complexes; boron etherates such as boron-THF complexes; boron -Amine complexes such as boron-ammonia, boron-tert-butylamine, boron-N-ethyl-diisopropylamine, boron-N-ethylmorpholine, boron-N-methylmorpholine, boron-morpholine, boron- Piperidine, boron-pyridine, boron-triethylamine, and boron-trimethylamine; boron-phosphine complexes such as boron-tributylphosphine or boron-triphenylphosphine; mixtures of borohydrides such as sodium borohydride and tetraalkylammonium borohydride; reagents that generate boranes in situ, such as sodium borohydride and iodine, sodium borohydride and BF 3 -diethyl etherate, sodium borohydride and chlorotrimethylsilane, tetraalkyl borohydride Combinations of ammonium and alkyl bromides such as n-butyl bromide; etc. Sodium borohydride in the presence of glacial acetic acid has generally been found to be a more suitable reducing agent in this step of the process of the invention.
该还原反应同样在合适的有机溶剂存在下进行。一般而言,非质子极性溶剂例如本文中所述的那些更适合于进行该还原步骤。这些有机溶剂的具体实例包括但不限于NMP、DMF、DMAc、THF、庚烷、己烷、甲苯、石油醚等。This reduction reaction is likewise carried out in the presence of a suitable organic solvent. In general, aprotic polar solvents such as those described herein are more suitable for carrying out this reduction step. Specific examples of these organic solvents include, but are not limited to, NMP, DMF, DMAc, THF, heptane, hexane, toluene, petroleum ether, and the like.
现已令人惊奇地发现极性非质子溶剂和非极性溶剂的混合物在进行该还原步骤中特别地提供了若干优点。这些溶剂混合物的具体实例包括但不限于NMP/庚烷、NMP/己烷、NMP/石油醚、DMF/己烷、DMF/正庚烷等。特别地,现已发现NMP和正庚烷的混合物在本发明的该方法中可提供某些优点,因为其可显著地减少试剂的发泡。It has now surprisingly been found that mixtures of polar aprotic and apolar solvents in particular offer several advantages in carrying out this reduction step. Specific examples of these solvent mixtures include, but are not limited to, NMP/heptane, NMP/hexane, NMP/petroleum ether, DMF/hexane, DMF/n-heptane, and the like. In particular, it has been found that a mixture of NMP and n-heptane can provide certain advantages in the process of the invention, since it can significantly reduce the foaming of the reagents.
式(IV)化合物到式(V)化合物的还原通常可以在产生所希望结果的任何温度下进行。因此,可以根据所使用的化合物和试剂的种类而采用亚环境温度至环境温度至超环境温度。一般而言,约0℃~约60℃的温度是合适的。通常采用约5℃~40℃的温度。优选约30℃的温度。The reduction of a compound of formula (IV) to a compound of formula (V) can generally be carried out at any temperature which produces the desired result. Thus, sub-ambient to ambient to super-ambient temperatures can be employed depending on the type of compound and reagent used. Generally, a temperature of from about 0°C to about 60°C is suitable. Typically a temperature of about 5°C to 40°C is employed. A temperature of about 30°C is preferred.
可以将式(V)化合物通过与合适的酸例如盐酸反应而作为合适盐例如盐酸盐进一步分离。一般而言,式(V)化合物的盐是结晶固体,并且因此提供了一种在将式(V)化合物于随后与式(VII)化合物反应中转化成式(VI)化合物之前如果需要的话提纯式(V)化合物的方法。Compounds of formula (V) may be further isolated as suitable salts such as hydrochloride by reaction with a suitable acid such as hydrochloric acid. In general, salts of compounds of formula (V) are crystalline solids, and thus provide a means for purification, if desired, prior to conversion of compounds of formula (V) to compounds of formula (VI) in subsequent reactions with compounds of formula (VII). A method for a compound of formula (V).
可以进行式(V)化合物与多种式(VII)的吡啶衍生物、优选与其中X是Cl和p为0的式(VII)化合物的反应以形成式(VI)化合物。这些式(VII)化合物的实例包括但不限于4-氯吡啶、4-氯-3-氟吡啶、4-氯-2-氟-吡啶和4-氯-3,5-二氟吡啶。The reaction of compounds of formula (V) with various pyridine derivatives of formula (VII), preferably with compounds of formula (VII) wherein X is Cl and p is 0, can be carried out to form compounds of formula (VI). Examples of such compounds of formula (VII) include, but are not limited to, 4-chloropyridine, 4-chloro-3-fluoropyridine, 4-chloro-2-fluoro-pyridine and 4-chloro-3,5-difluoropyridine.
该反应在先前方法步骤中所用的非质子极性溶剂例如但不限于NMP、DMF、DMAc、THF、庚烷、己烷、甲苯、石油醚等中,或者在极性非质子溶剂和非极性溶剂的混合物例如但不限于NMP/庚烷、NMP/己烷、NMP/石油醚、DMF/己烷、DMF/正庚烷等中进行。在本发明方法的该步骤中也可以使用多种其他溶剂。适合于该步骤的溶剂的实例包括:醚溶剂例如双(2-甲氧基乙基)醚、二乙醚、二甲氧基醚、二噁烷或THF;如本文中所述的极性非质子溶剂,其包括DMF、DMAc、HMPA或DMSO;或者质子溶剂例如甲醇、乙醇、异丙醇等。另外,如所述的那样,还可以使用这些溶剂的混合物的任何组合。一般而言,使用相同的溶剂例如NMP或者NMP和庚烷的混合物而进行该反应。The reaction is carried out in the aprotic polar solvent used in the previous method steps such as but not limited to NMP, DMF, DMAc, THF, heptane, hexane, toluene, petroleum ether, etc., or in a polar aprotic solvent and a nonpolar Mixtures of solvents such as but not limited to NMP/heptane, NMP/hexane, NMP/petroleum ether, DMF/hexane, DMF/n-heptane, etc. Various other solvents may also be used in this step of the method of the invention. Examples of solvents suitable for this step include: ether solvents such as bis(2-methoxyethyl) ether, diethyl ether, dimethoxy ether, dioxane or THF; polar aprotic solvents as described herein Solvents, which include DMF, DMAc, HMPA, or DMSO; or protic solvents such as methanol, ethanol, isopropanol, and the like. Additionally, any combination of mixtures of these solvents may also be used, as noted. In general, the reaction is carried out using the same solvent such as NMP or a mixture of NMP and heptane.
用于该步骤的合适的有机碱包括碱金属醇盐。合适的碱金属醇盐的实例包括但不限于甲醇锂、乙醇锂、异丙醇锂、叔丁醇锂、甲醇钠、乙醇钠、异丙醇钠、叔丁醇钠、甲醇钾、乙醇钾、异丙醇钾、叔丁醇钾、甲醇铯、乙醇铯、异丙醇铯、叔丁醇铯等;碱金属氢化物例如氢化钠或氢化钾等。也可以使用有机碱的混合物。已经发现,在实施本发明方法的该步骤中叔丁醇钾是特别合适的碱金属醇盐。Suitable organic bases for this step include alkali metal alkoxides. Examples of suitable alkali metal alkoxides include, but are not limited to, lithium methoxide, lithium ethoxide, lithium isopropoxide, lithium t-butoxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, sodium t-butoxide, potassium methoxide, potassium ethoxide, Potassium isopropoxide, potassium tert-butoxide, cesium methoxide, cesium ethoxide, cesium isopropoxide, cesium tert-butoxide, etc.; alkali metal hydrides such as sodium hydride or potassium hydride, etc. Mixtures of organic bases can also be used. Potassium tert-butoxide has been found to be a particularly suitable alkali metal alkoxide in carrying out this step of the process according to the invention.
通常可以在产生所希望结果的任何温度下进行式(V)化合物与吡啶衍生物(VII)反应以形成式(VI)化合物。因此,可以根据所使用的化合物和试剂的种类而采用亚环境温度至环境温度至超环境温度。一般而言,约70℃~约150℃的温度是合适的。The reaction of a compound of formula (V) with a pyridine derivative (VII) to form a compound of formula (VI) can generally be carried out at any temperature which produces the desired result. Thus, sub-ambient to ambient to super-ambient temperatures can be employed depending on the type of compound and reagent used. Generally, a temperature of about 70°C to about 150°C is suitable.
可以进一步将式(VI)化合物与合适的无机酸反应以得到式(VI)化合物的合适的盐。所述无机酸的一个实例是盐酸,从而得到式(VI)化合物的盐酸盐。一般而言,式(VI)化合物的盐是结晶固体,并且因此提供了一种在将式(VI)化合物用于例如药学目的之前如果需要的话提纯式(VI)化合物的方法。A compound of formula (VI) may be further reacted with a suitable mineral acid to obtain a suitable salt of the compound of formula (VI). An example of such an inorganic acid is hydrochloric acid, resulting in the hydrochloride salt of the compound of formula (VI). In general, salts of compounds of formula (VI) are crystalline solids and thus provide a means of purifying, if desired, compounds of formula (VI) prior to their use, eg, for pharmaceutical purposes.
可以在如上所述分离式(V)化合物之后在相同的反应容器中或者在不同的容器中进行该反应。可以使用本领域公知的任何反应器进行上述本发明的方法。此外,可以使用搅拌釜反应器、连续式反应器、微反应器或静态混合器。上述本发明的方法特别适合于在具有回路系统的静态混合器或者连续式搅拌釜反应器中进行所述偶联反应。有利的是,该反应以分批的方式操作。The reaction can be carried out in the same reaction vessel or in a different vessel after the compound of formula (V) is isolated as described above. The process of the invention described above can be carried out using any reactor known in the art. Furthermore, stirred tank reactors, continuous reactors, microreactors or static mixers can be used. The process of the invention described above is particularly suitable for carrying out the coupling reaction in a static mixer with a loop system or in a continuous stirred tank reactor. Advantageously, the reaction is operated in batch mode.
在本发明的另一方面中,本发明的一个实施方案包括根据本发明的该方法制备的产物。特别地,所制备的产物是N-(正丙基)-N-(3-氟-4-吡啶基)-1H-3-甲基吲哚-1-胺盐酸盐。In another aspect of the invention, an embodiment of the invention includes the product prepared according to the method of the invention. In particular, the product prepared was N-(n-propyl)-N-(3-fluoro-4-pyridyl)-1H-3-methylindole-1-amine hydrochloride.
在本发明的另一方面中还提供了一种式(IV)化合物,其中所述的取代基如本文中所述,条件是当R和R3是氢时,R4不是氢或甲基。In another aspect of the present invention there is also provided a compound of formula (IV), wherein said substituents are as described herein, with the proviso that when R and R3 are hydrogen, R4 is not hydrogen or methyl.
如所述的那样,式(IV)范围内的数种化合物是已知的并且因此将其从本发明中排除。例如,Somei等.Tet.Lett.No.41,3605-3608页(1974)描述了其中m=0,R1、R2、R3=H,R2=甲基,R4=甲基的式(IV)化合物,该文献的全部内容在此引入作为参考。As stated, several compounds within the scope of formula (IV) are known and are therefore excluded from the present invention. For example, Somei et al. Tet. Lett. No. 41, pages 3605-3608 (1974) describe wherein m = 0, R 1 , R 2 , R 3 = H, R 2 = methyl, R 4 = methyl Compounds of formula (IV), the entire content of which is hereby incorporated by reference.
在本发明的该实施方案的另一方面中,合适的式(IV)化合物是其中R、R1和R3是氢和R2是甲基的化合物。本发明范围内的具体化合物包括但不限于以下这些:In another aspect of this embodiment of the invention, suitable compounds of formula (IV) are those wherein R, R1 and R3 are hydrogen and R2 is methyl. Specific compounds within the scope of the present invention include, but are not limited to, the following:
3-甲基-N-(丙叉基)-1H-吲哚-1-胺;3-Methyl-N-(propylidene)-1H-indol-1-amine;
N-(丙叉基)-1H-吲哚-1-胺;N-(propylidene)-1H-indol-1-amine;
5-苄氧基-N-(丙叉基)-1H-吲哚-1-胺;5-Benzyloxy-N-(propylidene)-1H-indol-1-amine;
5-甲氧基-N-(丙叉基)-1H-吲哚-1-胺;5-methoxy-N-(propylidene)-1H-indol-1-amine;
和N-(丙叉基)-1H-咔唑-1-胺。and N-(propylidene)-1H-carbazol-1-amine.
通过以下实施例进一步阐述本发明,这些实施例是出于说明的目的而提供的并且决不限制本发明的范围。The present invention is further illustrated by the following examples, which are provided for the purpose of illustration and in no way limit the scope of the invention.
实施例(一般)Example (General)
在以下实施例中使用了下面的缩写:The following abbreviations are used in the following examples:
HOSA 羟胺-O-磺酸HOSA Hydroxylamine-O-sulfonic acid
HPLC 高效液相色谱HPLC High Performance Liquid Chromatography
KOtBu 叔丁醇钾KOtBu Potassium tert-butoxide
NMP N-甲基吡咯烷酮NMP N-Methylpyrrolidone
NMR 核磁共振光谱NMR nuclear magnetic resonance spectroscopy
用于表征的通用分析技术:将多种分析技术用于表征根据实践本发明制备的化合物,这些技术包括以下这些:使用Varian XL300或Gemini300分光光度计分别在300、75和282MHz下操作而记录1H、13C和19F NMR光谱。1H NMR光谱数据被表示为相对于作为内标的四甲基硅烷(TMS)以每百万的份数(ppm)计的δ,并且将以下缩写用于概括该数据:s=单峰,d=双重峰;t=三重峰;q=四重峰;m=多重峰;dd=双重峰中的双重峰;br=宽峰。在Perkin-Elmer Integral 4000液相色谱仪上通常使用3.9x150mm Waters Symmetry C18柱,5μ,乙腈/0.1N甲酸铵的平等流动相(isocratic mobile phase),流速1.0mL/分钟和UV探测收集HPLC数据。在Finnigan TSQ700分光计上获得质谱。通过Robertson Microlit,Inc进行元素分析。本文中使用的另一些缩写包括以下这些:LC=液相色谱;MS=质谱;EI/MS=电子喷射冲击/质谱仪;RT=停留时间;M+=分子离子。General Analytical Techniques Used for Characterization: A variety of analytical techniques were used to characterize the compounds prepared according to the practice of this invention, these techniques included the following: 1 H, 13C and19F NMR spectra. 1 H NMR spectral data are expressed as δ in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, and the following abbreviations are used to summarize the data: s = singlet, d = doublet; t = triplet; q = quartet; m = multiplet; dd = doublet of doublets; br = broad. HPLC data were typically collected on a Perkin-Elmer Integral 4000 liquid chromatograph using a 3.9x150 mm Waters Symmetry C 18 column, 5 μ, isocratic mobile phase of acetonitrile/0.1 N ammonium formate, flow rate 1.0 mL/min and UV detection . Mass spectra were acquired on a Finnigan TSQ700 spectrometer. Elemental analysis by Robertson Microlit, Inc. Other abbreviations used herein include the following: LC = Liquid Chromatography; MS = Mass Spectrometry; EI/MS = Electron Injection Impact/Mass Spectrometer; RT = Retention Time; M + = Molecular Ion.
实施例1Example 1
1H-吲哚-1-胺1H-Indole-1-amine
制备33.8kg(对于97%的纯度校正为32.8kg)的羟胺-O-磺酸(HOSA)和15.8kg(对于99%的纯度校正为15.6kg)的吲哚于120.2kg N-甲基吡咯烷酮(NMP)中的溶液并且冷却到0~5℃。由67.0kg(对于95%的纯度校正为63.7kg)的叔丁醇钾和122.6kg NMP制备另一溶液。向胺化容器装入47.0kg NMP和2.2kg叔丁醇钾/NMP溶液的初始进料。然后在185分钟内使用由双头柱塞泵和Coriolis质量流量计一起组成的计量泵系统将该HOSA/吲哚/NMP溶液和余下的叔丁醇钾/NMP溶液同时以及成比例地计量到胺化容器中,同时保持20~30℃的反应温度,得到通过外标HPLC分析测量含有15.9kg(90.2%的产率)的1H-吲哚-1-胺的溶液。Prepare 33.8 kg (32.8 kg corrected for 97% purity) of hydroxylamine-O-sulfonic acid (HOSA) and 15.8 kg (15.6 kg corrected for 99% purity) of indole in 120.2 kg N-methylpyrrolidone ( NMP) and cooled to 0-5°C. Another solution was prepared from 67.0 kg (63.7 kg corrected for 95% purity) of potassium tert-butoxide and 122.6 kg of NMP. The amination vessel was charged with an initial charge of 47.0 kg NMP and 2.2 kg potassium tert-butoxide/NMP solution. The HOSA/indole/NMP solution and the remaining potassium tert-butoxide/NMP solution were then metered simultaneously and proportionally to the amine within 185 minutes using a metering pump system consisting of a double-ended plunger pump and a Coriolis mass flow meter together. In a container while maintaining a reaction temperature of 20-30° C., a solution containing 15.9 kg (90.2% yield) of 1H-indol-1-amine was obtained as measured by external standard HPLC analysis.
实施例2Example 2
5-苄氧基-1H-吲哚-1-胺5-Benzyloxy-1H-indole-1-amine
制备5.3kg(对于97%的纯度校正为5.2kg)的羟胺-O-磺酸(HOSA)于19.1kg N-甲基吡咯烷酮(NMP)中的溶液并且冷却到0~5℃。由10.6kg(对于95%的纯度校正为10.0kg)的叔丁醇钾和19.3kg NMP制备另一溶液。向胺化容器装入5.0kg(对于94%的纯度校正为4.7kg)的5-苄氧基吲哚、15.5kg NMP和0.4kg叔丁醇钾/NMP溶液的初始进料。然后在166分钟内将该HOSA/NMP溶液和余下的叔丁醇钾/NMP溶液同时以及成比例地计量到胺化容器中,同时保持14~29℃的反应温度,得到通过外标HPLC分析测量的含有4.3kg(86.0%的产率)的5-苄氧基-1H-吲哚-1-胺的溶液。在加入105L水并且冷却到0~5℃之后,过滤该混合物。用63L醋酸正丁酯和8.5L水将滤出的固体分开,然后过滤。在降低的压力下将有机相浓缩,得到通过外标HPLC分析测量的含有3.9kg(77.4%的产率)的5-苄氧基-1H-吲哚-1-胺的固体。A solution of 5.3 kg (5.2 kg corrected for 97% purity) of hydroxylamine-O-sulfonic acid (HOSA) in 19.1 kg of N-methylpyrrolidone (NMP) was prepared and cooled to 0-5°C. Another solution was prepared from 10.6 kg (10.0 kg corrected for 95% purity) of potassium tert-butoxide and 19.3 kg of NMP. The amination vessel was charged with an initial charge of 5.0 kg (4.7 kg corrected for 94% purity) of 5-benzyloxyindole, 15.5 kg NMP and 0.4 kg potassium tert-butoxide/NMP solution. Then within 166 minutes, the HOSA/NMP solution and the remaining potassium tert-butoxide/NMP solution were simultaneously and proportionally metered into the amination vessel while maintaining a reaction temperature of 14-29°C, and the obtained solution was measured by external standard HPLC analysis. A solution containing 4.3 kg (86.0% yield) of 5-benzyloxy-1H-indol-1-amine. After adding 105 L of water and cooling to 0-5°C, the mixture was filtered. The filtered solid was separated with 63 L of n-butyl acetate and 8.5 L of water, then filtered. The organic phase was concentrated under reduced pressure to give a solid containing 3.9 kg (77.4% yield) of 5-benzyloxy-1H-indol-1-amine as measured by external standard HPLC analysis.
实施例3Example 3
5-甲氧基-1H-吲哚-1-胺5-Methoxy-1H-indole-1-amine
制备10.0g(对于97%的纯度校正为9.7g)的羟胺-O-磺酸(HOSA)于33.7g N-甲基吡咯烷酮(NMP)中的溶液并且冷却到0~5℃。由20-1g(对于95%的纯度校正为19.1g)的叔丁醇钾和34.4g NMP制备另一溶液。向胺化容器装入5.9g 5-甲氧基吲哚、17.8g NMP和0.7g叔丁醇钾/NMP溶液的初始进料。然后在86分钟内将该HOSA/NMP溶液和余下的叔丁醇钾/NMP溶液同时以及成比例地计量到胺化容器中,同时保持15~22℃的反应温度,得到通过内标HPLC分析测量的含有5.6g(87%的产率)的5-甲氧基-1H-吲哚-1-胺的溶液。A solution of 10.0 g (9.7 g corrected for 97% purity) of hydroxylamine-O-sulfonic acid (HOSA) in 33.7 g of N-methylpyrrolidone (NMP) was prepared and cooled to 0-5°C. Another solution was prepared from 20-1 g (19.1 g corrected for 95% purity) of potassium tert-butoxide and 34.4 g NMP. An initial charge of 5.9 g 5-methoxyindole, 17.8 g NMP, and 0.7 g potassium tert-butoxide/NMP solution was charged to the amination vessel. The HOSA/NMP solution and the remaining potassium tert-butoxide/NMP solution were then metered into the amination vessel simultaneously and proportionally within 86 minutes while maintaining a reaction temperature of 15-22°C to obtain an internal standard HPLC analysis. A solution containing 5.6 g (87% yield) of 5-methoxy-1H-indol-1-amine.
实施例4Example 4
1H-咔唑-1-胺1H-carbazol-1-amine
制备10.0g(对于97%的纯度校正为9.7g)的羟胺-O-磺酸(HOSA)于35.9g N-甲基吡咯烷酮(NMP)中的溶液并且冷却到0~5℃。第二种溶液由20.3g(对于95%的纯度校正为19.3g)的叔丁醇钾和35.3g NMP制备。向胺化容器装入7.0g(对于99%的纯度校正为6.7g)咔唑、21.7g NMP和1.3g叔丁醇钾/NMP溶液的初始进料。然后在86分钟内将该HOSA/NMP溶液和余下的叔丁醇钾/NMP溶液同时以及成比例地计量到胺化容器中同时保持22~30℃的反应温度,得到通过HPLC测量含有85%产率的1H-咔唑-1-胺的溶液。A solution of 10.0 g (9.7 g corrected for 97% purity) of hydroxylamine-O-sulfonic acid (HOSA) in 35.9 g of N-methylpyrrolidone (NMP) was prepared and cooled to 0-5°C. A second solution was prepared from 20.3 g (19.3 g corrected for 95% purity) of potassium tert-butoxide and 35.3 g NMP. An initial charge of 7.0 g (6.7 g corrected for 99% purity) of carbazole, 21.7 g of NMP, and 1.3 g of potassium tert-butoxide/NMP solution was charged to the amination vessel. The HOSA/NMP solution and the remaining potassium tert-butoxide/NMP solution were then metered simultaneously and proportionally into the amination vessel within 86 minutes while maintaining a reaction temperature of 22-30° C. rate of 1H-carbazol-1-amine solution.
实施例5Example 5
1H-3-甲基-吲哚-1-胺1H-3-Methyl-indole-1-amine
通过在氮气下将35.6kg叔丁醇钾和63.1kg N-甲基吡咯烷酮(NMP)装入30加仑的Hastelloy反应器和然后在20~25℃下搅拌30分钟而制备36.1%(wt/wt)的KOtBu/NMP溶液(足够用于2个胺化批料)。通过在氮气下将75.4kg NMP和总共为17.7kg的HOSA(在45分钟内分三份)装入30加仑的Hastelloy反应器、在30~35℃下搅拌40分钟(直到发生溶解),然后冷却到10℃而制备19.0%(wt/wt)的羟胺-O-磺酸(HOSA)于NMP中的溶液(足够用于2个胺化批料)。通过在氮气下将4.5kg(34.3mol)的3-甲基吲哚、10.0L的NMP和0.4kg(0.1当量)的叔丁醇钾装入30加仑玻璃衬里的反应器而准备胺化容器。使用由双头柱塞泵和一对质量流量计组成的成比例计量泵系统以同时以0.47kg/min泵送HOSA溶液和以0.49kg/min泵送KOtBu溶液到胺化反应器(通过胺化容器中表面下的喷射管)。通过调节夹套冷却将轻微放热的胺化过程的温度控制在25~35℃。在90分钟后停止进料,这时已经供入总共43.9kg的KOtBu溶液(4.1当量)和42.0kg的HOSA溶液(2.1当量),并且实现了97%的向N-氨基-3-甲基-吲哚的转化率(通过HPLC分析)。以两部分进行所述操作。将一半所述批料转移到含有60L冷水和12L甲苯的骤冷容器(30加仑的反应器)中。在20~25℃下搅拌10分钟后使所述相分离。用3×12-L部分的甲苯萃取水相。将另一半批料类似地进行处理。将得自于所述处理的每一部分的有机相合并并且浓缩(60℃,<50毫巴,50L旋转蒸发器),得到5.2kg作为糊状固体的N-氨基-3-甲基吲哚,其相应于通过NMR测量的对于溶剂(3.4wt%甲苯和6.9wt%NMP)校正为4.5kg的产物,89.7%产率,通过HPLC分析为95.9%纯度。36.1% (wt/wt) was prepared by charging 35.6 kg potassium tert-butoxide and 63.1 kg N-methylpyrrolidone (NMP) into a 30 gallon Hastelloy reactor under nitrogen and then stirring at 20-25°C for 30 minutes KOtBu/NMP solution (enough for 2 amination batches). By charging 75.4 kg of NMP and a total of 17.7 kg of HOSA (in three portions over 45 minutes) under nitrogen into a 30 gallon Hastelloy reactor, stirring at 30-35°C for 40 minutes (until dissolution occurs), then cooling A 19.0% (wt/wt) solution of hydroxylamine-O-sulfonic acid (HOSA) in NMP (enough for 2 amination batches) was prepared at 10°C. The amination vessel was prepared by charging 4.5 kg (34.3 mol) of 3-methylindole, 10.0 L of NMP, and 0.4 kg (0.1 equivalents) of potassium tert-butoxide into a 30 gallon glass lined reactor under nitrogen. A proportional metering pump system consisting of a double-head plunger pump and a pair of mass flow meters was used to simultaneously pump the HOSA solution at 0.47 kg/min and the KOtBu solution at 0.49 kg/min to the amination reactor (by amination Injection tubes below the surface in the container). The temperature of the slightly exothermic amination process was controlled at 25-35°C by adjusting the jacket cooling. Feeds were stopped after 90 minutes when a total of 43.9 kg of KOtBu solution (4.1 equiv) and 42.0 kg of HOSA solution (2.1 equiv) had been fed and 97% conversion to N-amino-3-methyl- Indole conversion (analyzed by HPLC). The operation was performed in two parts. Half of the batch was transferred to a quench vessel (30 gallon reactor) containing 60 L of cold water and 12 L of toluene. The phases were separated after stirring at 20-25°C for 10 minutes. The aqueous phase was extracted with 3 x 12-L portions of toluene. The other half of the batch was processed similarly. The organic phases from each fraction of the workup were combined and concentrated (60 °C, <50 mbar, 50 L rotary evaporator) to yield 5.2 kg of N-amino-3-methylindole as a pasty solid, This corresponds to 4.5 kg of product measured by NMR corrected for solvent (3.4 wt% toluene and 6.9 wt% NMP), 89.7% yield, 95.9% pure by HPLC analysis.
类似地,使用余下部分的HOSA和KOtBu溶液按照上述相同的步骤进行另外胺化,得到4.6kg(校正的)N-氨基-3-甲基吲哚,91.1%产率。Similarly, an additional amination was performed following the same procedure as above using the remaining portion of the HOSA and KOtBu solution to give 4.6 kg (corrected) N-amino-3-methylindole in 91.1% yield.
实施例6Example 6
1H-吲哚-1-胺1H-Indole-1-amine
步骤1-制备HOSA/吲哚溶液:在氮气吹扫和轻微排气下将120.2kg(116.3L)NMP装入50加仑玻璃衬里的钢制反应器,同时将反应器温度保持在19~23℃。伴随着搅拌(约130rpm)以大约15~30分钟间隔而通过人孔分三份(约15.8kg、9.0kg和9.0kg)供入33.8kg(对于97%的纯度校正成32.8kg)的HOSA。预计最初10~15℃升温的放热。使冷却水循环通过夹套或者采用温和的夹套加热以保持20~35℃的罐体温度(优选为30~35℃以有助于溶解)。预计在1~2小时搅拌后溶解。将反应器的内容物冷却到约20℃(10~25℃)的温度并且通过人孔供入15.8kg(对于99%的纯度校正成15.6kg)的吲哚。在溶解(数分钟)后,将反应器的内容物冷却到约0~5℃(-5至15℃)的温度,将搅拌降低至约50rpm并且然后将温度保持在约0~5℃(-5至15℃)进行该过程的其余部分。Step 1 - Preparation of HOSA/Indole solution: 120.2 kg (116.3 L) of NMP was charged into a 50 gallon glass-lined steel reactor under nitrogen purge and slight degassing while maintaining the reactor temperature at 19-23°C . 33.8 kg (corrected to 32.8 kg for 97% purity) of HOSA was fed through the manhole at approximately 15-30 minute intervals with stirring (approximately 130 rpm) in three portions (approximately 15.8 kg, 9.0 kg and 9.0 kg). An initial exotherm of 10-15°C warming is expected. Cooling water is circulated through the jacket or gentle jacket heating is used to maintain a tank temperature of 20-35°C (preferably 30-35°C to aid dissolution). It is expected to dissolve after stirring for 1-2 hours. The contents of the reactor were cooled to a temperature of about 20°C (10-25°C) and 15.8 kg (15.6 kg corrected for 99% purity) of indole were fed through the manhole. After dissolution (minutes), the contents of the reactor were cooled to a temperature of about 0-5°C (-5 to 15°C), the agitation was reduced to about 50 rpm and the temperature was then maintained at about 0-5°C (- 5 to 15°C) for the remainder of the process.
步骤2-制备叔丁醇钾溶液:在氮气吹扫和轻微排气下将122.6kg(118.7L)NMP装入50加仑玻璃衬里的装有空冷凝器管的钢制反应器,同时将反应器温度保持在约17~19℃(15~22℃)。在约150rpm(100~200rpm)的搅拌下通过人孔供入67.0kg(对于95%的纯度校正成63.7kg)的叔丁醇钾(KOtBu)。观察到轻微放热至20~25℃。在必要的情况下冷却以保持温度低于25℃。实现溶解(15~60分钟内)之后,在约50rpm和约17~25℃的温度下搅拌进行该过程的其余部分。Step 2 - Preparation of potassium tert-butoxide solution: 122.6 kg (118.7 L) of NMP was charged to a 50 gallon glass-lined steel reactor with an empty condenser tube under a nitrogen purge and slight degassing while the reactor The temperature is maintained at about 17-19°C (15-22°C). 67.0 kg (63.7 kg corrected for 95% purity) of potassium tert-butoxide (KOtBu) was fed through the manhole under stirring at about 150 rpm (100-200 rpm). A slight exotherm to 20-25°C was observed. Cool as necessary to keep the temperature below 25°C. After dissolution was achieved (within 15-60 minutes), the remainder of the process was carried out with stirring at about 50 rpm and a temperature of about 17-25°C.
步骤3-胺化:在氮气吹扫和轻微排气下将47.0kg(45.5L)NMP装入150加仑玻璃衬里的钢制反应器,并且伴随着约180rpm下的搅拌冷却到10~22℃。装入初始量的约0.05当量的得自于步骤2的KOtBu溶液(6.7mol,总共2.2kg的溶液)。然后于以下速率将以上在步骤1和2中制备的两种溶液同时泵送通过插在反应器顶部的相对侧(相隔约180度)的喷嘴中的喷射管(3/8英寸,外径304,SS管):得自于步骤1的HOSA/吲哚溶液在0.8L/min的速率下=0.9kg/min,总时间为187.4分钟;得自于步骤2的KOtBu溶液在1.0L/min的速率下=1.0kg/min,总时间为187.4分钟),同时保持良好的搅拌作用(>180rpm)和采用冷却水冷却将反应温度保持在约15~30℃,优选24~30℃。通过以供入的0.5当量HOSA进料间隔(每43分钟,在同时的试剂进料期间为35秒)取出反应混合物样品用于下面进一步详述的HPLC分析而监控反应进程。继续同时成比例地进料直到全部试剂(133.5mol刻度)已经供入并且如通过HPLC分析证实而判断出胺化结束。各自用5L NMP清洗来自步骤1和2的反应器并且在该步骤中将洗液泵送到150加仑的反应器中。然后将得自于该步骤的批料按现状用于n-丙叉基-1H-吲哚-1-胺制备中的下一步骤。Step 3 - Amination: 47.0 kg (45.5 L) of NMP was charged to a 150 gallon glass lined steel reactor under nitrogen purge and slight degassing and cooled to 10-22°C with stirring at about 180 rpm. An initial amount of about 0.05 equivalents of the KOtBu solution from step 2 (6.7 mol, total 2.2 kg of solution) was charged. The two solutions prepared above in steps 1 and 2 were then simultaneously pumped through injection tubes (3/8 inch, 304° OD) inserted in nozzles on opposite sides (about 180 degrees apart) of the top of the reactor at the following rates , SS tube): the HOSA/indole solution obtained from step 1 = 0.9 kg/min at a rate of 0.8 L/min, and the total time was 187.4 minutes; the KOtBu solution obtained from step 2 was obtained at a rate of 1.0 L/min Speed = 1.0kg/min, the total time is 187.4 minutes), while maintaining good stirring (> 180rpm) and using cooling water cooling to keep the reaction temperature at about 15-30°C, preferably 24-30°C. Reaction progress was monitored by withdrawing samples of the reaction mixture at 0.5 equivalent HOSA feed intervals (every 43 minutes, 35 seconds during simultaneous reagent feeds) for HPLC analysis as further detailed below. The simultaneous proportional feeds were continued until all reagents (133.5 mol mark) had been fed and the amination was judged to be complete as confirmed by HPLC analysis. The reactors from steps 1 and 2 were each rinsed with 5 L of NMP and the washes were pumped to the 150 gallon reactor in this step. The batch from this step was then used as is in the next step in the preparation of n-propylidene-1H-indol-1-amine.
采用以下条件通过HPLC分析监控反应混合物:The reaction mixture was monitored by HPLC analysis using the following conditions:
柱:Phenomenex,IB-SIL 5Phenyl,150×4.6mm,5微米Column: Phenomenex, IB-SIL 5Phenyl, 150×4.6mm, 5 microns
流动相:65∶35的0.1N甲酸铵/乙腈Mobile phase: 65:35 0.1N ammonium formate/acetonitrile
流速:1.5mL/minFlow rate: 1.5mL/min
探测:275nm的UVDetection: UV at 275nm
样品制备:用2mL 50∶50的流动相混合物稀释约15μL的反应混合物Sample preparation: Dilute approximately 15 µL of reaction mixture with 2 mL of 50:50 mobile phase mixture
注射量:10μLInjection volume: 10μL
实施例7Example 7
N-丙叉基-1H-吲哚-1-胺N-propylidene-1H-indole-1-amine
在氮气吹扫、轻微排气、约150rpm搅拌下于10~25℃(优选10~18℃)以及伴随着缓慢的夹套冷却以约1kg/min的速率将约21.6kg醋酸加入到根据实施例6中所述的步骤在150加仑钢制反应器中而制备的1H-吲哚-1-胺溶液中,直到pH为3.9~4.0(于5mL水中的0.1mL反应混合物)。如果需要,则装入逐渐增加的更多HOAc以保持pH水平。用约2L NMP清洗泵。基本以一份(大约1分钟的加入时间)供入10.8L水(预计温度轻微升高约3~6℃)。以约0.8kg/min(0.5~1.0kg/min)供入14.4kg(对于97%的纯度校正成13.9kg)的丙醛,同时保持10~24℃,优选10~20℃。预计温和放热。取决于添加和冷却速率,预计温度升高约5℃。用约3L NMP清洗泵。在10~24℃、优选17~20℃下搅拌直到通过其条件在下面进一步详述的HPLC分析证实而判断出反应结束(在2~3小时内转化率>99%)。通过取出反应混合物样品用于HPLC分析而监控反应进程。当判断出反应结束时,准备直接从反应器真空蒸馏到合适的接收器中。预计最初在50~70℃和约30~40mm压力下包含叔丁醇和水的挥发物初馏物(约45~50L)。当蒸馏速率减慢时,将罐体温度逐渐升高至95~100℃,将压力降低至5~25mm并且开始收集NMP。收集总共约320kg的馏出物(以得到相对于初始吲哚进料的罐体重量为9.5份w/w),然后用氮气释放真空并冷却至10~25℃。如果必要或者为了方便安排时间,则可以在任何时间中断蒸馏,这通过用氮气释放真空、冷却至<30℃、在氮气下储存并然后根据需要重新起动。通过反应器进料喷嘴(实现最大约为450L的工艺体积)装入133L庚烷,随后伴随着冷却水冷却以保持放热温度低于30℃,装入234L水而进行所述反应。搅拌>10分钟,然后使得所述相分离。用54L庚烷萃取底部水相。将有机萃取物合并,并且用碳酸氢钾水溶液(由溶于58L(58-95L)水中的0.6kg碳酸氢钾而制备)洗涤,随后用58L水洗涤。将有机相浓缩以得到作为油的粗制N-丙叉基-1H-吲哚-1-胺。通过短路径蒸馏而提纯,在约120℃蒸发器和约200~800毫巴压力下第一次通过以除去挥发物,然后在110℃蒸发器和0.2~0.4毫巴压力下第二次通过以收集经提纯的产物。Add about 21.6 kg of acetic acid at a rate of about 1 kg/min at a rate of about 1 kg/min at 10 to 25 ° C (preferably 10 to 18 ° C) under nitrogen purging, slight exhaust, and stirring at about 150 rpm. The procedure described in 6 was prepared in a 150 gallon steel reactor until the pH was 3.9-4.0 in 1H-indol-1-amine solution (0.1 mL reaction mixture in 5 mL water). If necessary, incrementally more HOAc was charged to maintain the pH level. Rinse the pump with about 2L of NMP. 10.8 L of water was fed essentially in one portion (approximately 1 minute addition time) (expect a slight temperature increase of approximately 3-6°C). 14.4 kg (13.9 kg corrected for a purity of 97%) of propionaldehyde is fed at about 0.8 kg/min (0.5-1.0 kg/min) while maintaining 10-24°C, preferably 10-20°C. A mild exotherm is expected. Depending on the rate of addition and cooling, a temperature increase of about 5°C is expected. Rinse the pump with about 3L of NMP. Stir at 10-24°C, preferably 17-20°C, until the reaction is judged to be complete (>99% conversion within 2-3 hours) as evidenced by HPLC analysis whose conditions are detailed further below. The progress of the reaction was monitored by taking a sample of the reaction mixture for HPLC analysis. When judged complete, the reaction was prepared to be vacuum distilled directly from the reactor into a suitable receiver. A volatile forerunt (about 45-50 L) containing tert-butanol and water is expected initially at 50-70°C and about 30-40 mm pressure. When the distillation rate slowed down, the tank temperature was gradually increased to 95-100° C., the pressure was reduced to 5-25 mm and NMP began to be collected. A total of about 320 kg of distillate was collected (to give a tank weight of 9.5 parts w/w relative to the initial indole charge), then the vacuum was released with nitrogen and cooled to 10-25°C. Distillations can be interrupted at any time if necessary or for scheduling convenience by releasing the vacuum with nitrogen, cooling to <30°C, storing under nitrogen and then restarting as needed. The reaction was carried out by charging 133 L of heptane through the reactor feed nozzle (to achieve a maximum process volume of approximately 450 L), followed by 234 L of water with cooling water to keep the exotherm temperature below 30°C. Stir for >10 minutes, then allow the phases to separate. The bottom aqueous phase was extracted with 54 L of heptane. The organic extracts were combined and washed with aqueous potassium bicarbonate (prepared from 0.6 kg potassium bicarbonate dissolved in 58 L (58-95 L) of water), followed by 58 L of water. The organic phase was concentrated to give crude N-propylidene-1H-indol-1-amine as an oil. Purified by short-path distillation with a first pass at an evaporator at about 120°C and a pressure of about 200-800 mbar to remove volatiles, followed by a second pass at an evaporator at 110°C at a pressure of 0.2-0.4 mbar to collect Purified product.
采用以下条件通过HPLC分析监控反应混合物:The reaction mixture was monitored by HPLC analysis using the following conditions:
柱:Phenomenex,IB-SIL 5Phenyl,150×4.6mm,5微米Column: Phenomenex, IB-SIL 5Phenyl, 150×4.6mm, 5 microns
流动相:65∶35的0.1N甲酸铵/乙腈Mobile phase: 65:35 0.1N ammonium formate/acetonitrile
流速:1.5mL/minFlow rate: 1.5mL/min
探测:275nm的UVDetection: UV at 275nm
样品制备:每1mL乙腈加入2滴反应混合物,注射量10μLSample preparation: Add 2 drops of reaction mixture per 1 mL of acetonitrile, injection volume 10 μL
实施例8Example 8
N-(丙叉基)-1H-吲哚-1-胺N-(propylidene)-1H-indole-1-amine
制备86.6g(771mmol)叔丁醇钾于160mL N-甲基吡咯烷酮(NMP)中的溶液。还制备36.4g(322mmol)羟胺-O-磺酸(HOSA)于175mL NMP中的溶液。在得到清澈溶液之后将HOSA溶液冷却到10℃。A solution of 86.6 g (771 mmol) of potassium tert-butoxide in 160 mL of N-methylpyrrolidone (NMP) was prepared. A solution of 36.4 g (322 mmol) of hydroxylamine-O-sulfonic acid (HOSA) in 175 mL of NMP was also prepared. The HOSA solution was cooled to 10 °C after a clear solution was obtained.
另外制备11.9g(102mmol)吲哚于20mL NMP中的溶液,将初始量为0.08~0.12当量的KOtBu溶液加入所述吲哚溶液中。然后在60分钟内于20℃下通过双注射泵将HOSA和KOtBu溶液同时以及成比例地加入反应混合物中。在该加入结束后,将9mL(500mmol)水、12mL(300mmol)冰醋酸和15mL(173mmol)丙醛加入到所得的深褐色悬浮液中。在20℃下搅拌该混合物直到反应结束。然后通过加入500mL水和200mL正庚烷而处理反应混合物。使得所述相分离。用300mL正庚烷再次萃取水相一次,并且再次用200mL甲苯萃取两次。用100mL水将合并的有机相洗涤两次。将所得的褐色庚烷溶液蒸发至干燥。这样产生14g作为褐色液体的N-(丙叉基)-1H-吲哚-1-胺(80%)。In addition, a solution of 11.9 g (102 mmol) of indole in 20 mL of NMP was prepared, and an initial amount of 0.08 to 0.12 equivalent of KOtBu solution was added to the indole solution. The HOSA and KOtBu solutions were then added simultaneously and proportionally to the reaction mixture by dual syringe pumps at 20 °C within 60 min. After this addition was complete, 9 mL (500 mmol) of water, 12 mL (300 mmol) of glacial acetic acid and 15 mL (173 mmol) of propionaldehyde were added to the resulting dark brown suspension. The mixture was stirred at 20°C until the reaction was complete. The reaction mixture was then worked up by adding 500 mL of water and 200 mL of n-heptane. The phases are allowed to separate. The aqueous phase was extracted once more with 300 mL of n-heptane and twice more with 200 mL of toluene. The combined organic phases were washed twice with 100 mL of water. The resulting brown heptane solution was evaporated to dryness. This yielded 14 g of N-(propylidene)-1H-indol-1-amine (80%) as a brown liquid.
沸点130~135℃(1.3~1.4毫巴)Boiling point 130-135°C (1.3-1.4 mbar)
1H-NMR(DMSO-d6,300MHz,TMS)[δ,ppm]:1.2(t,3H,CH3)、2.5(m,2H,CH2)、6.6(d,1H,芳族)、7.1(t,1H,芳族)、7.2(t,1H,芳族)、7.6(dd,2H,芳族)、8.0(d,1H,芳族)、8.2(t,1H,NCH) 1 H-NMR (DMSO-d 6 , 300 MHz, TMS) [δ, ppm]: 1.2 (t, 3H, CH 3 ), 2.5 (m, 2H, CH 2 ), 6.6 (d, 1H, aromatic), 7.1 (t, 1H, aromatic), 7.2 (t, 1H, aromatic), 7.6 (dd, 2H, aromatic), 8.0 (d, 1H, aromatic), 8.2 (t, 1H, NCH)
MS(EI+,70eV):172[M+],116[M+-NC3H6]MS (EI+, 70eV): 172 [M + ], 116 [M + -NC 3 H 6 ]
实施例9Example 9
N-丙基-1H-吲哚-1-胺N-Propyl-1H-indole-1-amine
制备12.3g(69.7mmol)N-(丙叉基)-1H-吲哚-1-胺于45mL NMP中的溶液,并且加入1.6g(41.8mol)的硼氢化钠。然后制备2.5g(41.8mmol)冰醋酸于15mL NMP中的溶液。在约30分钟内于30℃下将所述醋酸溶液加入到上面的反应混合物中。将立即出现氢气放出。在35℃下搅拌反应混合物直到反应结束。在反应结束时,通过在35℃下缓慢加入50mL水而处理反应混合物。在加入水期间注意使得将出现的发泡最小化并通过允许足够的顶部空间而用于发泡。将自由顶部空间保持达到反应器的液体内容物体积的三倍以控制发泡。用50mL正庚烷将反应混合物萃取、使得所述相分离并且再次用25mL正庚烷萃取水相。将合并的有机相蒸发至干燥。这样产生10.9g作为褐色液体的N-丙基-1H-吲哚-1-胺(90%)。A solution of 12.3 g (69.7 mmol) of N-(propylidene)-1H-indol-1-amine in 45 mL of NMP was prepared and 1.6 g (41.8 mol) of sodium borohydride was added. A solution of 2.5 g (41.8 mmol) of glacial acetic acid in 15 mL of NMP was then prepared. The acetic acid solution was added to the above reaction mixture at 30°C over about 30 minutes. Hydrogen evolution will occur immediately. The reaction mixture was stirred at 35°C until the reaction was complete. At the end of the reaction, the reaction mixture was worked up by slowly adding 50 mL of water at 35°C. Care was taken during water addition to minimize foaming that would occur and by allowing sufficient head space for foaming. Free headspace was maintained up to three times the volume of the liquid contents of the reactor to control foaming. The reaction mixture was extracted with 50 mL of n-heptane, the phases were allowed to separate and the aqueous phase was extracted again with 25 mL of n-heptane. The combined organic phases were evaporated to dryness. This yielded 10.9 g of N-propyl-1H-indol-1-amine (90%) as a brown liquid.
沸点115~125℃(1.1毫巴)Boiling point 115~125°C (1.1 mbar)
1H-NMR(DMSO-d6,300MHz,TMS)[δ,ppm]:0.9(t,3H,CH3)、1.35(m,2H,CH2)、3.0(m,2H,NCH2)、6.35(d,1H,芳族)、6.5(t,1H,NH)、7.0(t,1H,芳族)、7.15(t,1H,芳族)、7.4(m,1H,芳族)、7.5(dd,2H,芳族) 1 H-NMR (DMSO-d 6 , 300 MHz, TMS) [δ, ppm]: 0.9 (t, 3H, CH 3 ), 1.35 (m, 2H, CH 2 ), 3.0 (m, 2H, NCH 2 ), 6.35 (d, 1H, aromatic), 6.5 (t, 1H, NH), 7.0 (t, 1H, aromatic), 7.15 (t, 1H, aromatic), 7.4 (m, 1H, aromatic), 7.5 (dd, 2H, aromatic)
MS(EI+,70eV):174[M++H],131[M++H-NHC3H7]MS (EI+, 70eV): 174 [M + +H], 131 [M + +H-NHC 3 H 7 ]
实施例10Example 10
(3-氟吡啶-4-基)-(吲哚-1-基)-丙胺盐酸盐(3-Fluoropyridin-4-yl)-(indol-1-yl)-propylamine hydrochloride
制备18.0g叔丁醇钾于53mL NMP中的溶液,并且在20℃下将该悬浮液搅拌直到获得清澈溶液。将该溶液冷却至-20℃。向冷却溶液中加入9.3g(53.4mmol)N-丙基-1H-吲哚-1-胺、7.4g(53.4mmol)4-氯-3-氟吡啶和53mLNMP的混合物,同时将内部反应温度保持在约-15℃。在加入结束后在-20℃下搅拌该反应混合物约30分钟。然后将反应混合物加入到100mL水和13mL HCl(37%)中。然后加入50mL正庚烷(2×)并且使得所述相分离。将10mL NaOH(32%)加入到水相中并且用50mL醋酸正丁酯萃取水相两次,用50mL水洗涤合并的醋酸正丁酯相。将4.5mL HCl(37%)加入到所得的醋酸正丁酯相中。使用Dean-Stark阱将该混合物蒸馏以完全除去水。在蒸馏期间固体沉淀。将悬浮液冷却至5℃并过滤。在60~70℃下干燥之后留下10.8g作为浅黄色固体的(3-氟吡啶-4-基)-(吲哚-1-基)-丙胺盐酸盐(75%)。A solution of 18.0 g potassium tert-butoxide in 53 mL NMP was prepared and the suspension was stirred at 20 °C until a clear solution was obtained. The solution was cooled to -20°C. A mixture of 9.3 g (53.4 mmol) of N-propyl-1H-indol-1-amine, 7.4 g (53.4 mmol) of 4-chloro-3-fluoropyridine and 53 mL of NMP was added to the cooled solution while maintaining the internal reaction temperature at about -15°C. The reaction mixture was stirred at -20°C for about 30 minutes after the addition was complete. The reaction mixture was then added to 100 mL of water and 13 mL of HCl (37%). Then 50 mL of n-heptane (2x) was added and the phases were allowed to separate. 10 mL NaOH (32%) was added to the aqueous phase and the aqueous phase was extracted twice with 50 mL n-butyl acetate, the combined n-butyl acetate phases were washed with 50 mL water. 4.5 mL of HCl (37%) was added to the resulting n-butyl acetate phase. The mixture was distilled using a Dean-Stark trap to completely remove water. A solid precipitated during the distillation. The suspension was cooled to 5°C and filtered. 10.8 g of (3-fluoropyridin-4-yl)-(indol-1-yl)-propylamine hydrochloride (75%) remained as a pale yellow solid after drying at 60-70°C.
1H-NMR(DMSO d6,300MHz,TMS)[δ,ppm]:0.9(t,3H,CH3)、1.65(m,2H,CH2)、4.0(dm,2H,NCH2)、6.35(t,1H,芳族)、6.7(d,1H,芳族)、7.2(m,2H,芳族)、7.4(d,1H,芳族)、7.65(d,1H,芳族)、7.7(d,1H,芳族)、8.25(d,1H,芳族)、8.9(d,1H,芳族) 1 H-NMR (DMSO d 6 , 300 MHz, TMS) [δ, ppm]: 0.9 (t, 3H, CH 3 ), 1.65 (m, 2H, CH 2 ), 4.0 (dm, 2H, NCH 2 ), 6.35 (t, 1H, aromatic), 6.7 (d, 1H, aromatic), 7.2 (m, 2H, aromatic), 7.4 (d, 1H, aromatic), 7.65 (d, 1H, aromatic), 7.7 (d, 1H, aromatic), 8.25 (d, 1H, aromatic), 8.9 (d, 1H, aromatic)
MS(CI+):270[M++H,游离碱]MS(CI+): 270 [M + +H, free base]
实施例11Example 11
3-甲基-N-(丙叉基)-1H-吲哚-1-胺3-Methyl-N-(propylidene)-1H-indol-1-amine
制备44.7kg(398mol)叔丁醇钾于80kg N-甲基吡咯烷酮(NMP)中的溶液。另外制备21.5kg(190mol)羟胺-O-磺酸(HOSA)于98kg NMP中的溶液,并且在得到清澈液体之后将HOSA溶液冷却到10℃。A solution of 44.7 kg (398 mol) of potassium tert-butoxide in 80 kg of N-methylpyrrolidone (NMP) was prepared. A solution of 21.5 kg (190 mol) of hydroxylamine-O-sulfonic acid (HOSA) in 98 kg of NMP was additionally prepared, and after a clear liquid was obtained the HOSA solution was cooled to 10°C.
制备10kg(76.2mol)3-甲基吲哚于50kg NMP中的溶液,并且将初始量为0.08~0.12当量的KOtBu溶液加入到该3-甲基吲哚溶液中。在120分钟内于20℃下将所述HOSA和KOtBu溶液同时以及成比例地通过质量流量计加入到反应混合物中。在加入结束后,将6.9L(381mol)水、13.7kg(228.6mol)醋酸(100%)和7.5kg(129.2mol)丙醛加入到所得的深褐色悬浮液中。在20℃下搅拌该混合物约1小时直到反应结束。然后通过加入248L水和42kg正庚烷而处理反应混合物。不需要的盐从反应混合物中沉淀。将所得的悬浮液过滤并且使得所述相分离。再次用42kg正庚烷萃取水相3次。用63L水洗涤合并的有机相两次。将所得的褐色庚烷溶液蒸发至干燥。这样产生11.6~12.5kg作为褐色液体的3-甲基-N-(丙叉基)-1H-吲哚-1-胺(产率81~90%)。A solution of 10 kg (76.2 mol) of 3-methylindole in 50 kg of NMP was prepared, and an initial amount of 0.08-0.12 equivalents of KOtBu solution was added to the 3-methylindole solution. The HOSA and KOtBu solutions were simultaneously and proportionally added to the reaction mixture by mass flow meter at 20° C. within 120 minutes. After the addition was complete, 6.9 L (381 mol) of water, 13.7 kg (228.6 mol) of acetic acid (100%) and 7.5 kg (129.2 mol) of propionaldehyde were added to the resulting dark brown suspension. The mixture was stirred at 20°C for about 1 hour until the reaction was complete. The reaction mixture was then worked up by adding 248 L of water and 42 kg of n-heptane. Unwanted salts precipitated from the reaction mixture. The resulting suspension was filtered and the phases were allowed to separate. The aqueous phase was extracted 3 times again with 42 kg of n-heptane. The combined organic phases were washed twice with 63 L of water. The resulting brown heptane solution was evaporated to dryness. This yielded 11.6-12.5 kg of 3-methyl-N-(propylidene)-1H-indol-1-amine as a brown liquid (81-90% yield).
沸点121~123℃(1毫巴)Boiling point 121~123°C (1 mbar)
1H-NMR(300MHz,DMSO-d6,TMS)[δ,ppm]:1.15(t,3H,CH3)、2.3(s,3H,CH3)、2.45(m,2H,CH2)、7.05(t,1H,芳族)、7.2(t,1H,芳族)、7.5(2d,2H,芳族)、7.8(s,1H,芳族)、8.05(t,1H,NCH) 1 H-NMR (300MHz, DMSO-d 6 , TMS) [δ, ppm]: 1.15 (t, 3H, CH 3 ), 2.3 (s, 3H, CH 3 ), 2.45 (m, 2H, CH 2 ), 7.05(t, 1H, aromatic), 7.2(t, 1H, aromatic), 7.5(2d, 2H, aromatic), 7.8(s, 1H, aromatic), 8.05(t, 1H, NCH)
MS(CI+):187[M++H],130[M+-NC3H6]MS ( CI+): 187[M ++ H], 130[M + -NC3H6 ]
实施例12Example 12
3-甲基-N-丙基-1H-吲哚-1-胺3-Methyl-N-propyl-1H-indol-1-amine
在800L容器中制备3.0kg(74.4mol)硼氢化钠和26.8kg(124mol,86%纯度)3-甲基-N-(丙叉基)-1H-吲哚-1-胺于108kg NMP中的溶液。制备4.5kg(74.4mol)冰醋酸于27kg NMP中的溶液。在约30分钟内于30℃下将所述醋酸溶液加入到所述硼氢化钠溶液中。立即放出氢气。在30℃下搅拌该反应混合物直到反应结束(约1小时)。将6.3kg乙醇加入到反应混合物中,立即出现发泡。然后通过小心地加入另外的80L水而处理反应混合物。在加入水期间注意控制发泡,尤其建议在开始时缓慢加入水以避免不可控的发泡。注意确保当加入最初的1~2L水时没有出现发泡或者仅仅出现最少的发泡。将反应混合物静置过夜。用45kg正庚烷萃取水相三次,并且用66L水洗涤合并的有机相。将合并的有机相蒸发至干燥。这产生了22.4kg作为褐色液体的3-甲基-N-丙基-1H-吲哚-1-胺(产率90%,94%纯度)。Prepare 3.0kg (74.4mol) sodium borohydride and 26.8kg (124mol, 86% purity) 3-methyl-N-(propylidene)-1H-indol-1-amine in 108kg NMP in 800L container solution. A solution of 4.5 kg (74.4 mol) of glacial acetic acid in 27 kg of NMP was prepared. The acetic acid solution was added to the sodium borohydride solution at 30°C over about 30 minutes. Hydrogen gas was evolved immediately. The reaction mixture was stirred at 30°C until the reaction was complete (about 1 hour). 6.3 kg of ethanol was added to the reaction mixture and foaming occurred immediately. The reaction mixture was then worked up by carefully adding an additional 80 L of water. Take care to control foaming during water addition, and it is especially recommended to add water slowly at the beginning to avoid uncontrollable foaming. Care was taken to ensure that no or only minimal foaming occurred when the first 1-2 L of water was added. The reaction mixture was left to stand overnight. The aqueous phase was extracted three times with 45 kg of n-heptane, and the combined organic phases were washed with 66 L of water. The combined organic phases were evaporated to dryness. This yielded 22.4 kg of 3-methyl-N-propyl-1H-indol-1-amine (90% yield, 94% purity) as a brown liquid.
1H-NMR(300MHz,DMSO d6,TMS)[δ,ppm]:0.9(t,3H,CH3)、1.4(m,2H,CH2)、2.2(s,3H,CH3)、2.95(m,2H,NCH2)、6.3(t,1H,NH)、7.0(t,1H,芳族)、7.1(t,1H,芳族)、7.15(s,1H,芳族)、7.4(d,1H,芳族)、7.45(d,1H,芳族) 1 H-NMR (300MHz, DMSO d 6 , TMS) [δ, ppm]: 0.9 (t, 3H, CH 3 ), 1.4 (m, 2H, CH 2 ), 2.2 (s, 3H, CH 3 ), 2.95 (m, 2H, NCH 2 ), 6.3 (t, 1H, NH), 7.0 (t, 1H, aromatic), 7.1 (t, 1H, aromatic), 7.15 (s, 1H, aromatic), 7.4 ( d, 1H, aromatic), 7.45 (d, 1H, aromatic)
MS(CI+):189[M++H],130[M+-NC3H7]MS ( CI+): 189[M ++ H], 130[M + -NC3H7 ]
实施例13Example 13
3-甲基-N-丙基-1H-吲哚-1-胺3-Methyl-N-propyl-1H-indol-1-amine
制备硼氢化钠(4.54kg,120mol)于38kg NMP中的溶液。向该溶液中加入3-甲基-N-(丙叉基)-1H-吲哚-1-胺(38.6kg,190mol)于78kg正庚烷中的溶液。制备6.8kg(120mol)冰醋酸于32kg正庚烷中的溶液。在约30分钟内于30℃下使用泵将所述醋酸溶液加入到所述硼氢化钠溶液中。立即出现氢气放出。用3kg正庚烷清洗所述泵并将洗涤物添加至所述反应混合物中。在30℃下搅拌该反应混合物直到反应结束(约1小时)。然后通过加入76L水而处理反应混合物。在加入水期间没有观察到发泡或者仅仅观察到最少的发泡。搅拌该混合物过夜并且使得所述相分离。将2.82kg HCl(30%)和4.75kg水加入到正庚烷相中,检查pH,如果pH高于1则加入更多的HCl。将该混合物加热至75℃的内部温度达约2小时。冷却该混合物至25℃以控制氢气的放出。如果不再有残余氢气放出,则将pH水平调节至7、加入另外的30kg水、使得所述相分离并且用37kg水洗涤正庚烷相两次。将正庚烷相蒸发至干燥。这样产生37.5kg作为褐色液体的3-甲基-N-丙基-1H-吲哚-1-胺(98%)。A solution of sodium borohydride (4.54 kg, 120 mol) in 38 kg NMP was prepared. To this solution was added a solution of 3-methyl-N-(propylidene)-1H-indol-1-amine (38.6 kg, 190 mol) in 78 kg n-heptane. A solution of 6.8 kg (120 mol) of glacial acetic acid in 32 kg of n-heptane was prepared. The acetic acid solution was added to the sodium borohydride solution using a pump over about 30 minutes at 30°C. Hydrogen evolution occurred immediately. The pump was rinsed with 3 kg of n-heptane and the wash was added to the reaction mixture. The reaction mixture was stirred at 30°C until the reaction was complete (about 1 hour). The reaction mixture was then worked up by adding 76 L of water. No foaming or only minimal foaming was observed during the addition of water. The mixture was stirred overnight and the phases were allowed to separate. Add 2.82 kg HCl (30%) and 4.75 kg water to the n-heptane phase, check the pH and add more HCl if the pH is above 1. The mixture was heated to an internal temperature of 75°C for about 2 hours. The mixture was cooled to 25°C to control the evolution of hydrogen. If there is no more residual hydrogen evolution, the pH level is adjusted to 7, an additional 30 kg of water is added, the phases are allowed to separate and the n-heptane phase is washed twice with 37 kg of water. The n-heptane phase was evaporated to dryness. This yielded 37.5 kg of 3-methyl-N-propyl-1H-indol-1-amine (98%) as a brown liquid.
实施例14Example 14
(3-氟吡啶-4-基)-(3-甲基吲哚-1-基)-丙胺盐酸盐(3-fluoropyridin-4-yl)-(3-methylindol-1-yl)-propylamine hydrochloride
制备58.8kg叔丁醇钾于135.8kg NMP中的溶液,在20℃下搅拌该悬浮液直到获得清澈溶液,其被记作溶液A。A solution of 58.8 kg of potassium tert-butoxide in 135.8 kg of NMP was prepared and the suspension was stirred at 20°C until a clear solution was obtained, which was referred to as solution A.
制备36.1kg(175.6mol)3-甲基-N-丙基-1H-吲哚-1-胺和24.3kg(184.4mol)4-氯-3-氟吡啶于68.5kg NMP中的溶液,其被记作溶液B。A solution of 36.1 kg (175.6 mol) of 3-methyl-N-propyl-1H-indol-1-amine and 24.3 kg (184.4 mol) of 4-chloro-3-fluoropyridine in 68.5 kg of NMP was prepared, which was Call it solution B.
将如上制备的两种溶液A和B同时(约24kg/h溶液A和约17.2kg/h溶液B)加入到预先装有15kg NMP和2kg溶液A的反应器中,同时将内部温度保持在-20℃。通过使该混合溶液进入另一个容器而在将溶液A和B全部加入期间将该反应容器中的液体体积保持稳定在同一水平。用19kg水将由此收集于另一个容器中的反应溶液骤冷。在加入全部量的溶液A和B之后用20kg NMP洗涤反应器。为了进一步处理,加入275kg水并且用57kg正庚烷萃取所述碱性水相4次。用175kg水和13.2kg HCl(30%)将合并的正庚烷相萃取两次,使得所述相分离并且向所述水相中加入30.9kgNaOH溶液(33%)。用155kg醋酸正丁酯萃取水相两次并且用176kg水洗涤合并的醋酸正丁酯相。取出醋酸正丁酯萃取物样品以分析游离碱。基于该分析,将醋酸正丁酯相稀释至含有约10%的游离碱(w/w)。在真空下将水脱去并且将18.5kg HCl(30%)加入到所得的醋酸正丁酯相中。使用Dean-Stark阱蒸馏该混合物以完全除去水。在蒸馏期间固体沉淀。将悬浮液冷却至5℃并且过滤。用76kg醋酸正丁酯洗涤滤饼两次。在60~70℃下干燥之后留下43.8kg作为浅黄色固体的(3-氟吡啶-4-基)-(3-甲基吲哚-1-基)-丙胺盐酸盐(77.3%)。The two solutions A and B prepared as above were added simultaneously (approximately 24 kg/h solution A and approximately 17.2 kg/h solution B) into the reactor previously filled with 15 kg NMP and 2 kg solution A while maintaining the internal temperature at -20 ℃. The liquid volume in the reaction vessel was kept steady at the same level during the complete addition of solutions A and B by passing the mixed solution into another vessel. The reaction solution thus collected in another vessel was quenched with 19 kg of water. The reactor was washed with 20 kg NMP after adding the full amount of solutions A and B. For further work-up, 275 kg of water were added and the basic aqueous phase was extracted 4 times with 57 kg of n-heptane. The combined n-heptane phases were extracted twice with 175 kg water and 13.2 kg HCl (30%), the phases were allowed to separate and 30.9 kg NaOH solution (33%) was added to the aqueous phase. The aqueous phase was extracted twice with 155 kg of n-butyl acetate and the combined n-butyl acetate phases were washed with 176 kg of water. A sample of the n-butyl acetate extract was taken for free base analysis. Based on this analysis, the n-butyl acetate phase was diluted to contain about 10% free base (w/w). The water was removed under vacuum and 18.5 kg HCl (30%) was added to the resulting n-butyl acetate phase. The mixture was distilled using a Dean-Stark trap to completely remove water. A solid precipitated during the distillation. The suspension was cooled to 5°C and filtered. Wash the filter cake twice with 76kg n-butyl acetate. After drying at 60-70° C. 43.8 kg (3-fluoropyridin-4-yl)-(3-methylindol-1-yl)-propylamine hydrochloride (77.3%) remained as a pale yellow solid.
熔点219℃(DSC,加热速率5℃/分钟,HCl损失并分解)Melting point 219°C (DSC, heating rate 5°C/min, HCl loss and decomposition)
1H-NMR(300MHz,DMSO-d6,TMS)[δ,ppm]:0.9(t,3H,CH3)、1.7(m,2H,CH2)、2.5(m,3H,CH3)、4.0(dm,2H,CH2)、6.3(m,1H,芳族)、7.2(m,2H,芳族)、7.3(m,1H,芳族)、7.4(d,1H,芳族)、7.7(dd,1H,芳族)、8.2(d,1H,芳族)、8.9(d,1H,芳族) 1 H-NMR (300 MHz, DMSO-d 6 , TMS) [δ, ppm]: 0.9 (t, 3H, CH 3 ), 1.7 (m, 2H, CH 2 ), 2.5 (m, 3H, CH 3 ), 4.0 (dm, 2H, CH 2 ), 6.3 (m, 1H, aromatic), 7.2 (m, 2H, aromatic), 7.3 (m, 1H, aromatic), 7.4 (d, 1H, aromatic), 7.7 (dd, 1H, aromatic), 8.2 (d, 1H, aromatic), 8.9 (d, 1H, aromatic)
MS(EI+,70eV):283[M+,游离碱],240[M+-C3H7],130[3-甲基吲哚片段],96[氟吡啶片段]MS (EI+, 70eV): 283[M + , free base], 240[M + -C 3 H 7 ], 130[3-methylindole fragment], 96[fluoropyridine fragment]
实施例15Example 15
4-氯-3-氟吡啶4-Chloro-3-fluoropyridine
在氮气下将2.5kg(25.8mol)3-氟吡啶、3.4kg(29.6mol,1.2当量)四甲基乙二胺(TMEDA)和20L甲基叔丁基醚(MTBE)装入30加仑Hastelloy反应器。将该溶液冷却至-50℃。在24分钟内加入总共15.5L(12.6L,29.6mol,1.15当量)的1.9M二异丙基氨化锂(LDA)溶液(庚烷/THF/乙基苯),同时保持-40至-48℃的温度。在-44至-48℃下将该浅褐色悬浮液搅拌50分钟。在48分钟内加入7kg(29.6mol,1.15当量)六氯乙烷于20L MTBE中的溶液,同时保持-40至-46℃的温度。在-40℃下搅拌20分钟后将反应加热至0℃,然后骤冷入含有54L冷水的反应器。在20~25℃下搅拌20分钟后,通过硅藻土过滤该混合物以使得微小的乳液破裂。分离所述层。用5L MTBE萃取水层。将有机层合并,然后用数份(1×21L,3×13L)的2N HCl萃取。将酸性水相合并,用16L MTBE分隔,然后通过加入6.5kg 50%的NaOH而碱化至pH 6.19,同时保持15~20℃的温度。分离所述层。用10L MTBE萃取水相。在3.0kg硫酸钠上将合并的有机相干燥、然后过滤并且浓缩(56℃,在大部分浓缩期间为575毫巴,对于最终浓缩则为400毫巴),得到3.7kg作为褐色液体的4-氯-3-氟吡啶,通过NMR对于31.2%的溶剂校正为2.4kg,通过HPLC纯度为95.5%,产率为70.2%。2.5 kg (25.8 mol) of 3-fluoropyridine, 3.4 kg (29.6 mol, 1.2 equiv) of tetramethylethylenediamine (TMEDA), and 20 L of methyl tert-butyl ether (MTBE) were charged to a 30 gallon Hastelloy reaction under nitrogen device. The solution was cooled to -50°C. A total of 15.5 L (12.6 L, 29.6 mol, 1.15 equiv) of 1.9 M lithium diisopropylamide (LDA) solution (heptane/THF/ethylbenzene) was added over 24 minutes while maintaining -40 to -48 °C temperature. The beige suspension was stirred at -44 to -48°C for 50 minutes. A solution of 7 kg (29.6 mol, 1.15 equiv) of hexachloroethane in 20 L of MTBE was added over 48 minutes while maintaining a temperature of -40 to -46°C. After stirring at -40°C for 20 minutes the reaction was warmed to 0°C and then quenched into a reactor containing 54 L of cold water. After stirring at 20-25° C. for 20 minutes, the mixture was filtered through celite to break a fine emulsion. The layers were separated. The aqueous layer was extracted with 5L MTBE. The organic layers were combined and extracted with several portions (1 x 21 L, 3 x 13 L) of 2N HCl. The acidic aqueous phases were combined, separated with 16 L of MTBE, and then basified to pH 6.19 by adding 6.5 kg of 50% NaOH while maintaining a temperature of 15-20 °C. The layers were separated. The aqueous phase was extracted with 10 L MTBE. The combined organic phases were dried over 3.0 kg sodium sulfate, then filtered and concentrated (56 °C, 575 mbar during most of the concentration, 400 mbar for the final concentration) to give 3.7 kg of 4- Chloro-3-fluoropyridine, 2.4 kg corrected for 31.2% solvent by NMR, 95.5% pure by HPLC, 70.2% yield.
实施例16Example 16
(3-氟吡啶-4-基)-(3-甲基吲哚-1-基)-丙胺盐酸盐(3-fluoropyridin-4-yl)-(3-methylindol-1-yl)-propylamine hydrochloride
制备510g(4.5mol)叔丁醇钾于1190g NMP中的溶液,在20℃下搅拌该悬浮液直到获得清澈溶液(溶液A)。A solution of 510 g (4.5 mol) of potassium tert-butoxide in 1190 g of NMP was prepared and the suspension was stirred at 20° C. until a clear solution was obtained (solution A).
制备154.1g(769mmol,94%纯度)3-甲基-N-丙基-1H-吲哚-1-胺、112.7g(846mmol,99%纯度)4-氯-3-氟吡啶和622g NMP的溶液(溶液B)。Preparation of 154.1 g (769 mmol, 94% purity) of 3-methyl-N-propyl-1H-indol-1-amine, 112.7 g (846 mmol, 99% purity) of 4-chloro-3-fluoropyridine and 622 g of NMP solution (Solution B).
将950g溶液A装入回路系统,其与连续式搅拌釜反应器(CSTR)和带有环形泵的静态混合器相连。将该回路系统冷却至-15℃。开始将溶液A装入CSTR并且从静态混合器中装入溶液B,在温度控制(-15℃)下加入两种溶液53分钟。在加入期间将CSTR中的体积保持恒定在约360mL。用247g水将反应混合物骤冷。在进料结束后将回路系统排空并且用951g水洗涤该系统。将另外的1224g水加入到所述洗涤物和骤冷的反应溶液中。用380g正庚烷萃取水相4次。用771g水和45.4g HCl(37%)的溶液萃取所得的正庚烷相两次。向所得的水相中加入131g NaOH(33%)并且用680g醋酸正丁酯萃取两次。用775g水将所得的醋酸正丁酯相洗涤一次。加入79.6g HCl(37%)并且使用Dean-Stark阱在真空下将所得的混合物蒸馏,直到不再移出水。当产物开始结晶时将反应混合物冷却至5℃,并且过滤产物。在盘式干燥器中在真空下干燥。这样产生164.4g 3-氟吡啶-4-基-(3-甲基吲哚-1-基)-丙胺盐酸盐(产率71%)。950 g of solution A were charged to a loop system connected to a continuous stirred tank reactor (CSTR) and a static mixer with a ring pump. The loop system was cooled to -15°C. The CSTR was initially charged with solution A and solution B from the static mixer, both solutions were added under temperature control (-15°C) for 53 minutes. The volume in the CSTR was kept constant at about 360 mL during the addition. The reaction mixture was quenched with 247 g of water. After the feed was complete the loop system was emptied and the system was washed with 951 g of water. An additional 1224 g of water was added to the washes and quenched reaction solution. The aqueous phase was extracted 4 times with 380 g of n-heptane. The resulting n-heptane phase was extracted twice with a solution of 771 g of water and 45.4 g of HCl (37%). To the resulting aqueous phase was added 131 g of NaOH (33%) and extracted twice with 680 g of n-butyl acetate. The resulting n-butyl acetate phase was washed once with 775 g of water. 79.6 g HCl (37%) was added and the resulting mixture was distilled under vacuum using a Dean-Stark trap until no more water was removed. The reaction mixture was cooled to 5°C when the product started to crystallize, and the product was filtered. Dry under vacuum in a tray dryer. This gave 164.4 g of 3-fluoropyridin-4-yl-(3-methylindol-1-yl)-propylamine hydrochloride (71% yield).
实施例17Example 17
N-(丙叉基)-1H-吲哚-1-胺N-(propylidene)-1H-indole-1-amine
制备26.8kg(239mol)叔丁醇钾(KOtBu)于50kg N-甲基吡咯烷酮(NMP)中的溶液。另外制备13.8kg(120mol)羟胺-O-磺酸(HOSA)于7lkg NMP中的溶液,并且在获得清澈液体之后将HOSA溶液冷却至10℃。A solution of 26.8 kg (239 mol) potassium tert-butoxide (KOtBu) in 50 kg N-methylpyrrolidone (NMP) was prepared. A solution of 13.8 kg (120 mol) of hydroxylamine-O-sulfonic acid (HOSA) in 71 kg of NMP was additionally prepared and the HOSA solution was cooled to 10° C. after obtaining a clear liquid.
制备6.4kg(54.6mol)吲哚于25kg NMP中的溶液。在180分钟内将如上制备的HOSA和KOtBu溶液同时以及成比例地通过质量流量计加入到该溶液中,并且将反应混合物保持在15℃。在加入结束之后向所得的深褐色悬浮液中加入4.3L(239mol)水、9.7kg(161.5mol)醋酸(100%)和5.3kg(91.3mol)丙醛。在20℃下搅拌该混合物约1小时直到反应结束。然后通过加入180L水和21kg正庚烷而处理反应混合物。不需要的盐从反应混合物中沉淀。过滤所得的悬浮液并且使得所述相分离。再次用21kg正庚烷萃取水相4次。用45L水洗涤合并的有机相两次。将所得的褐色庚烷溶液蒸发至15~25%的溶液。这样产生6.3~7.0kg作为褐色液体的N-(丙叉基)-1H-吲哚-1-胺(对于19.7~24.1%分析校正的产率为67~74%)。A solution of 6.4 kg (54.6 mol) of indole in 25 kg of NMP was prepared. The HOSA and KOtBu solutions prepared above were simultaneously and proportionally added to this solution by mass flow meter within 180 minutes, and the reaction mixture was kept at 15°C. To the resulting dark brown suspension were added 4.3 L (239 mol) of water, 9.7 kg (161.5 mol) of acetic acid (100%) and 5.3 kg (91.3 mol) of propionaldehyde after the addition had ended. The mixture was stirred at 20°C for about 1 hour until the reaction was complete. The reaction mixture was then worked up by adding 180 L of water and 21 kg of n-heptane. Unwanted salts precipitated from the reaction mixture. The resulting suspension was filtered and the phases were allowed to separate. The aqueous phase was extracted 4 times again with 21 kg of n-heptane. The combined organic phases were washed twice with 45 L of water. The resulting brown heptane solution was evaporated to a 15-25% solution. This yielded 6.3-7.0 kg of N-(propylidene)-1H-indol-1-amine as a brown liquid (67-74% yield corrected for 19.7-24.1% assay).
1H-NMR(400MHz,DMSO-d6,TMS)[δ,ppm]:1.19(t,3H,CH3)、2.48(m,2H,CH2)、6.60(d,1H,芳族)、7.08(t,1H,芳族)、7.22(t,1H,芳族)、7.57(d,1H,芳族)、7.61(d,1H,芳族)、8.03(d,1H,芳族)、8.19(t,1H,NCH) 1 H-NMR (400MHz, DMSO-d 6 , TMS) [δ, ppm]: 1.19 (t, 3H, CH 3 ), 2.48 (m, 2H, CH 2 ), 6.60 (d, 1H, aromatic), 7.08 (t, 1H, aromatic), 7.22 (t, 1H, aromatic), 7.57 (d, 1H, aromatic), 7.61 (d, 1H, aromatic), 8.03 (d, 1H, aromatic), 8.19 (t, 1H, NCH)
MS(ES+):173[M++H],117[M+-NC3H6]MS(ES+): 173[M ++ H], 117[M + -NC 3 H 6 ]
实施例18Example 18
N-丙基-1H-吲哚-1-胺N-Propyl-1H-indole-1-amine
制备0.83kg(21.9mol)硼氢化钠于16.6kg NMP中的溶液。加入31.9kgA solution of 0.83 kg (21.9 mol) sodium borohydride in 16.6 kg NMP was prepared. Add 31.9kg
N-(丙叉基)-1H-吲哚-1-胺作为于正庚烷(36.5mol)中的19.7%溶液和另外的7.7kg正庚烷。制备1.32kg(21.9mol)冰醋酸于2.8kg正庚烷中的溶液。在约30分钟内于30℃下使用泵将所述醋酸溶液加入到硼氢化钠溶液中。将立即出现氢气放出。用2kg正庚烷洗涤泵。在30℃下搅拌该反应混合物直到反应结束(约1小时)。通过加入20L水而处理反应混合物。在加入水期间没有观察到发泡或者仅仅观察到最少的发泡。搅拌该混合物过夜并且使得所述相分离。将0.9kgHCl(30%)和3.4kg水加入到正庚烷相中,检验pH是否低于1。如果必要,则加入附加量的HCl以调节pH约为1。将该混合物加热至75℃的内部温度达约2小时。将该混合物冷却至25℃以控制放出的残余氢气。如果不再有残余氢气放出,则加入附加的20.3kg水并且用NaOH(33%)调节pH至>7的水平。使得所述相分离并且用20.3kg水洗涤正庚烷相。将正庚烷相蒸发至干燥。这样产生5.84kg作为褐色液体的N-丙基-1H-吲哚-1-胺(82.6%)。N-(propylidene)-1H-indol-1-amine as a 19.7% solution in n-heptane (36.5 mol) and an additional 7.7 kg of n-heptane. A solution of 1.32 kg (21.9 mol) of glacial acetic acid in 2.8 kg of n-heptane was prepared. The acetic acid solution was added to the sodium borohydride solution using a pump over about 30 minutes at 30°C. Hydrogen evolution will occur immediately. Wash the pump with 2 kg of n-heptane. The reaction mixture was stirred at 30°C until the reaction was complete (about 1 hour). The reaction mixture was worked up by adding 20 L of water. No foaming or only minimal foaming was observed during the addition of water. The mixture was stirred overnight and the phases were allowed to separate. Add 0.9 kg HCl (30%) and 3.4 kg water to the n-heptane phase and check if the pH is below 1. Additional amounts of HCl were added to adjust the pH to approximately 1, if necessary. The mixture was heated to an internal temperature of 75°C for about 2 hours. The mixture was cooled to 25°C to control evolution of residual hydrogen. If there is no more residual hydrogen evolution, an additional 20.3 kg of water are added and the pH is adjusted to a level >7 with NaOH (33%). The phases were allowed to separate and the n-heptane phase was washed with 20.3 kg of water. The n-heptane phase was evaporated to dryness. This yielded 5.84 kg of N-propyl-1H-indol-1-amine (82.6%) as a brown liquid.
1H-NMR(400MHz,DMSO-d6,TMS)[δ,ppm]:0.91(t,3H,CH3)、1.35(m,2H,CH2)、3.00(m,2H,CH2)、6.33(d,1H,芳族)、6.43(t,1H,NH)、7.12(t,1H,芳族)、6.98(t,1H,芳族)、7.35(d,H,芳族)、7.46(d,1H,芳族)、7.50(d,1H,芳族) 1 H-NMR (400MHz, DMSO-d 6 , TMS) [δ, ppm]: 0.91 (t, 3H, CH 3 ), 1.35 (m, 2H, CH 2 ), 3.00 (m, 2H, CH 2 ), 6.33 (d, 1H, aromatic), 6.43 (t, 1H, NH), 7.12 (t, 1H, aromatic), 6.98 (t, 1H, aromatic), 7.35 (d, H, aromatic), 7.46 (d, 1H, aromatic), 7.50 (d, 1H, aromatic)
MS(ES+):175[M++H]MS(ES+): 175[M ++ H]
实施例19Example 19
吲哚-1-基-丙基-吡啶-4-基-胺盐酸盐Indol-1-yl-propyl-pyridin-4-yl-amine hydrochloride
制备12.4kg(110.7mol)叔丁醇钾于23.6kg NMP中的溶液,在20℃下搅拌该悬浮液直到获得清澈溶液(溶液A)。A solution of 12.4 kg (110.7 mol) of potassium tert-butoxide in 23.6 kg of NMP was prepared and the suspension was stirred at 20° C. until a clear solution was obtained (solution A).
制备5.84kg)27.7mol,分析结果82.6%)N-丙基-1H-吲哚-1-胺和4.36kg(29.1mol)4-氯吡啶盐酸盐于15kg NMP中的第二溶液(溶液B)。Prepare 5.84kg) 27.7mol, analytical result 82.6%) N-propyl group-1H-indol-1-amine and 4.36kg (29.1mol) the second solution (solution B) of 4-chloropyridine hydrochloride in 15kg NMP ).
将溶液A加入溶液B中,同时将温度保持在20℃。搅拌1小时并检验反应的完成。在135kg水中将所述反应混合物骤冷。用HCl(30%)将所述溶液的pH值调节至约2并且用20kg正庚烷萃取两次。去除有机层。用NaOH(33%)将水层的pH值调节至12并且用16kg醋酸正丁酯萃取两次。去除水层。用23kg水洗涤有机层。在20℃下将10.8kg甲醇HCl(29.9mol,分析结果10.1%)加入有机层。在结晶后将该混合物冷却至5℃,过滤产物并且用醋酸正丁酯洗涤。在盘式干燥器中于真空、80℃下干燥。这将产生5.8kg作为白色至米色固体的吲哚-1-基-丙基-吡啶-4-基-胺氯化氢(产率73%)。Solution A was added to solution B while maintaining the temperature at 20°C. Stir for 1 hour and check for completion of the reaction. The reaction mixture was quenched in 135 kg of water. The pH of the solution was adjusted to about 2 with HCl (30%) and extracted twice with 20 kg n-heptane. Remove the organic layer. The pH of the aqueous layer was adjusted to 12 with NaOH (33%) and extracted twice with 16 kg n-butyl acetate. Remove the aqueous layer. The organic layer was washed with 23 kg of water. 10.8 kg methanolic HCl (29.9 mol, analysis 10.1%) was added to the organic layer at 20°C. After crystallization the mixture was cooled to 5°C, the product was filtered and washed with n-butyl acetate. Dry in a tray dryer under vacuum at 80°C. This will yield 5.8 kg of indol-1-yl-propyl-pyridin-4-yl-amine hydrochloride as a white to beige solid (73% yield).
1H-NMR(400MHz,DMSO-d6,TMS)[δ,ppm]:0.94(t,3H,CH3)、1.62(m,2H,CH2)、4.05(dm,2H,CH2)、6.74(d,1H,芳族)、7.19(m,1H,芳族)、7.28(m,1H,芳族)、7.30(d,1H,芳族)、5.8~7.6(sv br,2H,芳族)、7.63(d,1H,芳族)、7.70(d,1H,芳族)、8.43(d br,2H,芳族)、15.2(s br,1H,NH+) 1 H-NMR (400MHz, DMSO-d 6 , TMS) [δ, ppm]: 0.94 (t, 3H, CH 3 ), 1.62 (m, 2H, CH 2 ), 4.05 (dm, 2H, CH 2 ), 6.74 (d, 1H, aromatic), 7.19 (m, 1H, aromatic), 7.28 (m, 1H, aromatic), 7.30 (d, 1H, aromatic), 5.8~7.6 (sv br, 2H, aromatic family), 7.63 (d, 1H, aromatic), 7.70 (d, 1H, aromatic), 8.43 (d br, 2H, aromatic), 15.2 (s br, 1H, NH + )
MS(ES+):252[M++H,游离碱]MS(ES+): 252 [M + +H, free base]
下面的实施例阐述了通过按照EP0249452中所述的步骤获得的N-胺化产物。The following examples illustrate N-aminated products obtained by following the procedure described in EP0249452.
比较例1Comparative example 1
1H-吲哚-1-胺1H-Indole-1-amine
制备3.3g(对于97%的纯度校正为3.2g)羟胺-O-磺酸(HOSA)于7.7g水中的溶液并且冷却至0~5℃。将10.0g吲哚和50.0g水装入胺化容器。然后在120分钟内将HOSA/水溶液和7.3mL 30%的NaOH溶液同时计量到胺化容器中,同时保持20~25℃的反应温度。HPLC分析表明没有形成1H-吲哚-1-胺。A solution of 3.3 g (3.2 g corrected for 97% purity) of hydroxylamine-O-sulfonic acid (HOSA) in 7.7 g of water was prepared and cooled to 0-5°C. 10.0 g of indole and 50.0 g of water were charged to the amination vessel. The HOSA/water solution and 7.3 mL of 30% NaOH solution were then simultaneously metered into the amination vessel within 120 minutes while maintaining a reaction temperature of 20-25°C. HPLC analysis indicated no formation of 1H-indole-1-amine.
尽管已经通过某些在前的实施例阐述了本发明,但不认为由此限制了本发明;相反,本发明包括了如上文中所披露的一般范围。在不偏离其精神和范围的情况下可以作出多种变换方案和实施方案。While the invention has been illustrated by certain preceding examples, it is not to be considered as limited thereby; rather, the invention encompasses the general scope as disclosed hereinabove. Various changes and embodiments can be made without departing from its spirit and scope.
Claims (55)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50833503P | 2003-10-03 | 2003-10-03 | |
| US60/508,335 | 2003-10-03 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101707936A Division CN101391976A (en) | 2003-10-03 | 2004-10-01 | Process for preparing N-amino substituted heterocyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1890213A true CN1890213A (en) | 2007-01-03 |
| CN100579963C CN100579963C (en) | 2010-01-13 |
Family
ID=34434904
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200480035790A Expired - Fee Related CN100579963C (en) | 2003-10-03 | 2004-10-01 | Process for preparing N-amino substituted heterocyclic compounds |
| CNA2008101707936A Pending CN101391976A (en) | 2003-10-03 | 2004-10-01 | Process for preparing N-amino substituted heterocyclic compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101707936A Pending CN101391976A (en) | 2003-10-03 | 2004-10-01 | Process for preparing N-amino substituted heterocyclic compounds |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7112682B2 (en) |
| EP (1) | EP1678135B1 (en) |
| JP (1) | JP2007507518A (en) |
| KR (1) | KR20060120028A (en) |
| CN (2) | CN100579963C (en) |
| AR (1) | AR046041A1 (en) |
| AT (1) | ATE431339T1 (en) |
| AU (1) | AU2004279808B2 (en) |
| BR (1) | BRPI0415002A (en) |
| CA (1) | CA2540867A1 (en) |
| DE (1) | DE602004021126D1 (en) |
| DK (1) | DK1678135T3 (en) |
| ES (1) | ES2327417T3 (en) |
| HR (2) | HRP20090441T1 (en) |
| IL (1) | IL174238A0 (en) |
| MA (1) | MA28117A1 (en) |
| ME (1) | MEP19508A (en) |
| MX (1) | MXPA06003446A (en) |
| NO (1) | NO20061929L (en) |
| NZ (1) | NZ545838A (en) |
| PL (1) | PL1678135T3 (en) |
| PT (1) | PT1678135E (en) |
| RS (1) | RS20060225A (en) |
| RU (1) | RU2364588C2 (en) |
| SI (1) | SI1678135T1 (en) |
| TW (1) | TW200519086A (en) |
| WO (1) | WO2005035496A1 (en) |
| ZA (1) | ZA200602694B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105753838A (en) * | 2016-02-11 | 2016-07-13 | 安阳师范学院 | Novel high-regioselectivity amination method of quinoline derivatives |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039774A1 (en) * | 2002-05-01 | 2005-03-02 | Wyeth Corp | 6-BICYCLE RENTAL-PENEMS AS BETA-LACTAMASAS INHIBITORS |
| AR039475A1 (en) * | 2002-05-01 | 2005-02-23 | Wyeth Corp | 6-ALQUILIDEN-PENEMS TRICICLICOS AS BETA-LACTAMASA INHIBITORS |
| AR039476A1 (en) * | 2002-05-01 | 2005-02-23 | Wyeth Corp | PROCESS TO PREPARE DERIVATIVES OF 6-RENT PENEM |
| US20040132708A1 (en) * | 2002-05-01 | 2004-07-08 | Wyeth | Process for preparing 6-alkylidene penem derivatives |
| US7538227B2 (en) * | 2004-01-13 | 2009-05-26 | Sanofi-Aventis Deutschland Gmbh | Process for stabilizing 4-halopyridines |
| WO2006115456A1 (en) * | 2005-04-26 | 2006-11-02 | Cambrex Karlskoga Ab | Synthesis of 1-aminopiperidine |
| WO2007027323A2 (en) * | 2005-07-27 | 2007-03-08 | Wyeth | TRICYCLIC 6-ALKYLIDENE-PENEM β-LACTAMASE INHIBITORS AND β-LACTAM ANTIBIOTIC COMBINATION: A BROAD SPECTRUM ANTIBIOTIC |
| JP2009502934A (en) * | 2005-07-27 | 2009-01-29 | ワイス | Bicyclic 6-alkylidene penem β-lactamase inhibitors and β-lactam antibiotic combinations: broad spectrum antibiotics |
| GT200600380A (en) * | 2005-08-24 | 2007-03-29 | BETA-LACTAMASA INHIBITORS PREPARATION PROCESS | |
| FR2897614B1 (en) * | 2006-02-20 | 2008-05-23 | Urogene | CRYSTALLINE FORM OF BESIPIRDINE HYDROCHLORIDE, METHODS OF PREPARATION AND USES |
| EP2493305B1 (en) * | 2009-10-30 | 2015-03-25 | Genzyme Corporation | 2-aminoindole compounds and methods for the treatment of malaria |
| EP3623378B1 (en) * | 2017-05-12 | 2025-07-02 | Chugai Seiyaku Kabushiki Kaisha | Method for producing cyclic organic compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0629273B2 (en) | 1986-06-13 | 1994-04-20 | 宇部興産株式会社 | Process for producing N-aminohexamethyleneimine |
| JPH01157922A (en) * | 1987-12-15 | 1989-06-21 | Citizen Watch Co Ltd | Production of nitrile compound |
| US5459274A (en) * | 1994-05-13 | 1995-10-17 | Hoechst-Roussel Pharmaceuticals Inc. | Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines |
-
2004
- 2004-09-30 AR ARP040103557A patent/AR046041A1/en not_active Application Discontinuation
- 2004-10-01 SI SI200431204T patent/SI1678135T1/en unknown
- 2004-10-01 CN CN200480035790A patent/CN100579963C/en not_active Expired - Fee Related
- 2004-10-01 DE DE602004021126T patent/DE602004021126D1/en not_active Expired - Lifetime
- 2004-10-01 RU RU2006114667/04A patent/RU2364588C2/en not_active IP Right Cessation
- 2004-10-01 ME MEP-195/08A patent/MEP19508A/en unknown
- 2004-10-01 KR KR1020067006835A patent/KR20060120028A/en not_active Ceased
- 2004-10-01 AU AU2004279808A patent/AU2004279808B2/en not_active Ceased
- 2004-10-01 ES ES04785294T patent/ES2327417T3/en not_active Expired - Lifetime
- 2004-10-01 CN CNA2008101707936A patent/CN101391976A/en active Pending
- 2004-10-01 HR HR20090441T patent/HRP20090441T1/en unknown
- 2004-10-01 CA CA002540867A patent/CA2540867A1/en not_active Abandoned
- 2004-10-01 WO PCT/US2004/032086 patent/WO2005035496A1/en not_active Ceased
- 2004-10-01 TW TW093129738A patent/TW200519086A/en unknown
- 2004-10-01 US US10/957,124 patent/US7112682B2/en not_active Expired - Lifetime
- 2004-10-01 DK DK04785294T patent/DK1678135T3/en active
- 2004-10-01 JP JP2006534079A patent/JP2007507518A/en not_active Abandoned
- 2004-10-01 BR BRPI0415002-3A patent/BRPI0415002A/en not_active IP Right Cessation
- 2004-10-01 NZ NZ545838A patent/NZ545838A/en unknown
- 2004-10-01 RS RSP-2006/0225A patent/RS20060225A/en unknown
- 2004-10-01 AT AT04785294T patent/ATE431339T1/en not_active IP Right Cessation
- 2004-10-01 MX MXPA06003446A patent/MXPA06003446A/en active IP Right Grant
- 2004-10-01 EP EP04785294A patent/EP1678135B1/en not_active Expired - Lifetime
- 2004-10-01 PT PT04785294T patent/PT1678135E/en unknown
- 2004-10-01 HR HR20060124A patent/HRP20060124A2/en not_active Application Discontinuation
- 2004-10-01 PL PL04785294T patent/PL1678135T3/en unknown
-
2006
- 2006-03-09 IL IL174238A patent/IL174238A0/en unknown
- 2006-03-31 ZA ZA200602694A patent/ZA200602694B/en unknown
- 2006-04-28 NO NO20061929A patent/NO20061929L/en not_active Application Discontinuation
- 2006-04-28 MA MA28977A patent/MA28117A1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105753838A (en) * | 2016-02-11 | 2016-07-13 | 安阳师范学院 | Novel high-regioselectivity amination method of quinoline derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1269820C (en) | New pyrrole derivatives as drugs | |
| CN1072669C (en) | Benzimidazole compounds and their use as modulators of the GABAA receptor complex | |
| CN1165537C (en) | Pyrroloindoles, pyridoindoles and aza * -indoles as 5-HT 2C agonists | |
| CN1036456C (en) | Amino-substituted pyrazoles | |
| CN1053190C (en) | Quinoxalindione derivs., their preparation and their use in drugs | |
| CN1211382C (en) | Quinazoline xylene sulfonate compound | |
| CN1308326C (en) | Process for preparing indolinone derivatives | |
| CN1832927A (en) | Novel gamma-secretase inhibitors | |
| CN1845921A (en) | Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as DPP-IV inhibitors | |
| CN1826319A (en) | Aryl-heteroaromatic compounds, compositions comprising them and use | |
| CN1890213A (en) | Process for preparing N-amino-substituted heterocyclic compounds | |
| CN1608050A (en) | Piperazine derivative | |
| CN1649827A (en) | Preparation method of highly functionalized γ-butyrolactam and γ-amino acid | |
| CN1230432C (en) | Substituted phenyl-Piperazine derivatives, their preparation and use | |
| CN1726196A (en) | Pyrazine-based tubulin inhibitors | |
| CN1922150A (en) | Indazole derivatives and pharmaceutical compositions containing them | |
| CN1930105A (en) | Method for preparation of a fluoroaromatic compound from an aminoaromatic amine compound | |
| CN1249052C (en) | Pyrazole derivatives as HIV reverse transcriptase inhibitors | |
| CN1157390C (en) | Indole derivatives | |
| CN1227253C (en) | Process for the preparation of sulfonamide substituted imidazotriazinones | |
| CN1771234A (en) | Process for preparing pyrrolotriazine kinase inhibitors | |
| CN1950083A (en) | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | |
| CN1186346C (en) | Thienopyrrolidinones | |
| CN1109051A (en) | 3-(Phenylaminoalkoxy)-5-phenylpyrazole, preparation method, intermediate and drug | |
| CN1390834A (en) | Indenoindolone compounds, their preparation and medicinal compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1095592 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1095592 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100113 Termination date: 20101001 |